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7. DPP- 4i- Dipeptidyl peptidase 4 inhibitors 
8. SGLT- 2-Sodium Glucose co –transport – 2  
9. GIP-Glucose dependent insulinotropic polypeptide 
10.  HBA1c -Glycosylated haemoglobin 
11.  OHA-Oral hypoglycaemic agent  
12. FPG-Fasting plasma glucose 
13. PPG-Post prandial glucose 
14.  BSA- Bovine serum albumin 
15.  AIR -acute insulin response 
16. OGTT-Oral glucose tolerance test  
17. LDL-c - Low density lipoprotein cholesterol 
18. HDL-c - High density lipoprotein cholesterol 
19. TGL-Triglyceride 
20. TC-Total cholesterol 
21. AMPK-Activated protein kinase  
22. OAT-Organic anion transporter  
23. OATP-Organic anion transporting polypeptide  
24. CrCl- Creatinine clearance  
25. ESRD-End-Stage renal disease 
26.  FDA-Food and drug administration 
27. GOD/POD-Glucose oxidase peroxidase 
28. SMBG-Self Monitoring blood glucose 
29. GIPRS- Glucose dependent insulinotropic peptide receptors 
30. ADA- American diabetes association 
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INTRODUCTION 
                         Diabetes Mellitus (DM) commonly called as diabetes, is a group of 
metabolic disorders characterized by elevated blood sugar levels over a prolonged 
period. It is a condition in which the body does not produce or respond to insulin, a 
hormone that regulates the level of glucose in the blood. It may be due to lack of 
secretion of enough insulin by the pancreas or the non-responsiveness of beta cells of 
pancreas to the insulin produced. It is characterized by increased thirst, frequent 
urination, high blood sugar and increased appetite. Diabetes is classified in to various 
categories, among which the most common categories are, Type 1 Diabetes Mellitus, 
Type 2 Diabetes Mellitus and Gestational Diabetes. 
Type 1 DM is otherwise known as juvenile diabetes. In this type the pancreas is not 
able to produce enough insulin and the cause is unknown. Type 2 DM is also called as 
Adult onset diabetes. It is a condition where the cells do not respond properly to 
insulin secretion and finally ends in insulin resistance. Gestational diabetes is 
characterized by pregnant mother with high blood sugar but without a previous history 
of diabetes.  
Other specific types of DM are genetic defect of beta cell dysfunction-Maturity Onset 
Diabetes mellitus of the Young (MODY 1 to 6) and genetic defect in insulin 
action.(Type A insulin resistance) 
[1]
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PREVALANCE: 
             Type 1 DM accounts for 5 to 10% and Type 2 DM accounts for 90 to 95% of 
diabetic population. The incidence of both the types are rising all over the world .Type 
2 DM is increasing rapidly and has become a global epidemic. It depends on the 
lifestyle of the individual and social changes among the population. It is estimated that 
in the year 2000, 171 million people had diabetes and this is expected to be double by 
2030. It may rise up to addition of 79.4 million in India, 42.3 million in China and in 
United States (US) it will be about 30.3 million. The rough estimation showed that 
prevalence is one quarter in rural population when compared with urban population. 
The national survey conducted across the metropolitan cities of India (YEAR) 
reported that percentage of people with diabetes is very less in north India compared 
to cities in south India (13.5% in Chennai, 16.6% in Hyderabad and 12.4% in 
Bangalore). Rising prevalence of Type 2 DM is mainly because of consumption of 
foods with high lipid and glucose content. In India, people got adopted to sedentary 
life style which leads to lack of exercise and weight gain. These factors lead to 
increase in the prevalence rate of diabetes in south India. 
[2]
 
Uncontrolled Type 2 DM plays an important role in the development of 
pathophysiological events that may lead to micro vascular and macro vascular 
complications. They are impaired insulin secretion, peripheral insulin resistance and 
excessive hepatic glucose production. It provokes a cascade of changes in endothelial, 
mesangial, smooth muscle and macrophage cell function in a manner which results in 
micro and macro vascular diseases. Microvascular changes are retinopathy, 
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neuropathy and nephropathy. Macro vascular manifestations are atherosclerosis 
leading to cardiovascular diseases and metabolic syndrome due to changes in the 
carbohydrate and lipid metabolism. To avoid these complications and to keep the 
plasma glucose under control, many newer drugs have been invented. About seven 
classes of oral hypoglycemic agents are currently in use in the management of Type 2 
DM. They are Sulfonylureas, Meglitinide/ Phenylalanine analogues, Biguanides, 
Thiazolidinediones, Alpha-glucosidase inhibitors, Glucagon – like peptide – 1 
receptor agonist, DPP-4 Inhibitor, SGLT2 Inhibitor and Amylin analogue. 
           Many oral hypoglycemic agents after repeated usage, they lose their efficacy 
resulting in inadequate glycemic control and adverse effects. So, there is need to 
invent newer drugs in the management of Type 2 DM to overcome the limitations 
associated with other medications. It has been found that there is reduced response 
produced by incretin hormones in diabetes and this defect results in the discovery of 
incretin based therapy in 2005. Two types of drugs are available in the clinical 
practice such as GLP- 1 agonist and DPP- 4 Inhibitors, Dipeptidyl peptidase 4 
inhibitors (DPP-4i) have got a good therapeutic approach in the treatment of diabetes. 
So far, six DPP- 4i have been invented and all are available in the market for clinical 
practice.  They are – Sitagliptin, Vildagliptin, Alogliptin, Saxagliptin, Linagliptin and 
Tenegliptin. The novel oral antidiabetic drugs are Dopamine D2 agonist approved by 
FDA in 2009 and Sodium Glucose Co Transport 2 (SGLT- 2) inhibitor. SGLT- 2 
inhibitor is under trial and tolerability and safety of this drug is yet to be established. 
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DPP- 4 inhibitors act by enhancing the levels of active incretin hormones and 
thereby it reduces the plasma glucose level. Eating stimulates the secretion of multiple 
gastrointestinal hormones that regulates the gut motility, secretion of gastric acid, 
pancreatic enzymes, gall bladder contractions and nutrient absorption. One among 
them is incretin hormones.  They are of two types such as Glucagon like peptide (GLP 
- 1) and Glucose dependent insulinotropic polypeptide (GIP). Both are released from 
the intestinal cells following meal ingestion. The GLP -1 stimulates insulin secretion 
from the pancreatic beta cells and GIP inhibits the glucagon secretion from the 
pancreatic alpha cells. These incretin hormones are inactivated by DPP - 4 enzyme as 
soon as they are released from the intestinal cells. DPP -4 enzyme is an 
aminopeptidase expressed in many tissues such as liver, lung, kidney, intestinal brush 
border membranes, lymphocytes and endothelial cells. Many gastrointestinal 
hormones, neuropeptides and cytokines are substrates of DPP -4 enzyme. 
              DPP – 4 inhibitors reduces serum DPP – 4 activity by more than 80 % 
thereby it reduces the glycosylated hemoglobin HBA1c, fasting plasma glucose and 
postprandial plasma glucose levels. It has got a very good safety and efficacy profile 
in the treatment of Type 2 DM. About six DPP – 4 inhibitors are available in the 
market for the treatment of Type 2 DM. Sitagliptin was the first drug discovered and 
approved by USA FDA in October 2006 and European Union in March 2007. 
Vildagliptin a selective DPP -4 inhibitor was invented and approved in February 2007, 
saxagliptin in 2009 and alogliptin in 2010. These are found to be associated with less 
hypoglycemic symptoms, weight gain, gastrointestinal distress and produces a 
significant reduction in HBA1c and fasting and postprandial plasma glucose levels 
[3].
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Sitagliptin, a first DPP -4i has been found to be very effective Oral Hypoglycemic 
Agent (OHA) in Type 2 DM patients. It is available orally and can be used as 
monotherapy or as a combined therapy with other oral hypoglycemic agents. It can be 
used as an adjuvant therapy with insulin. It significantly reduces HBA1c, fasting and 
postprandial glucose levels . When sitagliptin given as an adjuvant therapy with 
sulfonylureas and Biguanides, it decreases the side effects produced by them 
[3].
 With 
insulin, it improves the metabolic control and lipid profile by reducing low density 
lipoprotein cholesterol level and thereby it reduces the insulin need 
[3].
 In cardiac 
patients with coronary artery disease and Type 2 DM, it improves the cardiac 
function, coronary artery perfusion and prevents the complications 
[4].
 Many clinical 
trials showed that sitagliptin significantly reduces HBA1c, fasting plasma glucose and 
postprandial glucose levels when administered as monotherapy or combined therapy 
with other oral hypoglycemic agents . 
Vildagliptin, a second selective DPP – 4i was approved by US FDA in February 2007. 
It is an orally active, effective, potent drug and well tolerated by patients with Type 2 
DM. When administered orally, it inhibits DPP – 4 activity at different doses and has 
got quick onset of action. It improves the beta cell function on the basis of 
pharmacodynamics modelling and the sensitivity of alpha cells to glucose for both 
suppressive as well as stimulatory effect. It significantly reduces HBA1c, fasting 
plasma glucose and postprandial glucose levels. It has less hypoglycemic symptoms 
and weight neutralizing property when administered as monotherapy or add on 
therapy with other oral hypoglycemic agents. It inhibits the triglyceride absorption 
from the gut and thereby it reduces the low density lipoprotein cholesterol level. It 
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does not affect the gastric emptying and has got good gastrointestinal safety profile 
[5].
 
Compared with sitagliptin Long term trials have proved that Vildagliptin  to be an 
effective, safe and well tolerable drug in elderly patients with  Type 2 DM when given 
along with other oral hypoglycemic agents 
[5].
 
The advantages of DPP- 4 inhibitors in Type 2 DM patients are, insulin release is 
glucose dependent, suppress glucagon release, improves beta cell health and retard 
progression of beta cell failure, neutralizes body weight, mostly single daily dose, well 
tolerated with few side effects, no serious toxicity and no drug interactions expect 
with Saxagliptin 
[6].
 
Few studies showed that sitagliptin significantly reduces the lipid profile (Abdul  
Hussein  et al 2011, Tremblay et al 2011, Akira Kubota et al 20l2). There is a 
controversial study demonstrated that there was no significant difference in the lipid 
profile after treatment with sitagliptin (Hidekatsu yanai et al 2012) and Vildagliptin, 
reduces the triglycerides absorption from the gut there by it neutralizes the weight in 
type 2 diabetes mellitus patients.  
Recently studies are ongoing to evaluate the effect of DPP- 4 inhibitors in preventing 
the cardiovascular complications in type 2 DM patients. There are some limited and 
controversial studies available regarding the effect of sitagliptin and vildagliptin on 
lipid profile, so this study is structured to evaluate the comparative effect of both the 
drugs on glycemic control and lipid profile in type 2 DM patients. 
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AIMS AND OBJECTIVES: 
The aim of this study is to evaluate the effect of sitagliptin and vildagliptin on 
glycemic control ( fasting blood sugar ,postprandial blood sugar,HbA1c) in type 2 
diabetes mellitus patients with hyperglycemia not controlled by other therapies and 
also to evaluate the effect of both the drugs on lipid profile in these patients. 
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REVIEW LITERATURE 
Diabetes mellitus (DM) is a major health problem, which results in 
hyperglycemia due to failure of pancreas to secrete enough insulin or the body cells 
not responding to the insulin secreted. Diabetes, when not treated properly leads to 
many complications. Long term complications are cardiovascular disease, cerebro 
vascular accidents, chronic renal failure, ulcer foot and blindness. Type I DM 
accounts for 5% to 10% and Type II accounts for 90 to 95% of all cases of diabetes 
mellitus. The prevalence of type II diabetes mellitus is increasing day by day.  
There are various types of diabetes mellitus based on the etiology. Etiological 
classification of diabetes and other specific causes are as: Type 1 DM such as, Beta 
cell destruction usually leading to absolute insulin deficiency, Autoimmune and 
Idiopathic. In Type II DM there is predominately insulin resistance. In Gestational 
diabetes mellitus (GDM) there is glucose intolerance developing or recognized during 
pregnancy. Other specific types of diabetes are, Genetic defects of beta cell 
dysfunction; eg Mody 1 to 6, Genetic defects in insulin action (eg) Type A insulin 
resistance, Disease of exocrine pancreas (eg) fibro calculus pancreatopahty, 
Endocrinopathies (eg) acromegaly & cushings, Drugs or chemical induced (eg) 
glucocorticoids, Infections (eg) congenital rubella, Uncommon forms of immune 
mediated diabetes, (eg) stiff man syndrome, Other genetic syndromes 
[1] 
. 
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AETIOPATHOGENESIS OF TYPE 1 DM: 
Type I diabetes is a slowly progressive T cell – mediated autoimmune disease. It has a 
high degree of prevalence in certain populations. It occur in subjects below 25 years 
though the age is exempt. Genetic autoimmunity play a determining role in the 
etiologic of type 1 DM. The pathophysiological picture in the pre-diabetic pancreas in 
type I diabetes is characterized by Insulitis Infiltration of the islets with mononuclear 
cells containing activated macrophages, helper cytotoxic and suppressor T 
lymphocytes, Natural killer cells and B lymphocytes. Other features are striking B cell 
specificity of the destructive process, with the glucagon and other hormone secreting 
cells in the islet invariably remains intact. 
The Genetic factors involved in DM are twin studies, histocompatibility 
antigen and insulin gene. In the twin studies; about 10% of type I DM subjects have a 
sibling or parent with the disease. Studies of monozytic twins have established about 
30 -50% concordance for type I DM among identical twins if one of them develops 
type 1 DM the co – twin has a 30 to 50% chance of developing the disease. Purely 
genetic disease will be associated with a 100% concordance in monozygotic twins, 
Evidences of genetic factors in the causation of type 1 DM come from vicious 
animals, human twin and family studies. 
In the genetic factor of histocompatibility antigen, the concordance of type 1 
DM in genetically identical twins is 40-60% indicating a significant genetic 
component. The major genetic risk is conferred by HLA Class II genes encoding 
HLA-DR and HLA-DQ. Insulin gene is located in the short aim of chromosome 11. 
The changes in the nucleotide flanking the gene have been reported in type 1 DM. 
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Immunological factors:  
Severed evidences suggest that the hum oral and cell mediated – Auto immune 
response leads to destruction of beta cells. Demonstration of circulating antibodies 
(GG1244) to islet – cells, cell radiated abnormalities in type 1 DM patients presenting 
with “ insulitis”  - all conforms the autoimmune pathogenic mechanism. 
Viruses and toxins (environmental factors):  
Mumps, coxsackie B4, retroviruses, rubella, cytomegalovirus, epstien barr virus. 
Dietary factory : 
Dietary factors may influence the development of type I Diabetes such as 
consumption of cow‟s milk during early life may be contribution to environmental 
factor associated with type 1 DM. Bovine Serum albumin (BSA)n, a major constituent 
of cow‟s milk , has been implicated in triggering type 1 diabetes. The bovine serum 
albumin an antigen may enter in an intact from through the gut of neonates and 
stimulate an immune response directed against B cells. Another dietary factor linked 
to the causation of diabetes is the „nitrosamines‟ found in smoked and cured meats  
Genetic Susceptibility 
Environmental Trigger 
(Vines / Toxins) 
Immunological activation 
(Autoimmunity) 
                                               Progressive Beta cell destruction 
Type 1 DM 
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Aetiopathogenesis of type 2 DM: 
Aetiopathogenesis type 2 Diabetes is or more complex from type I DM. The role of 
genetic factors in the etiologic of type 2 DM has been appreciated ever since the 
recognition of the disease. Type 2 DM is probably homozygous in nature involving 
triple abnormalities in the genesis of hyperglycaemia, such as impaired pancreatic 
insulin secretion, peripheral resistance to insulin a chain occurring primarily in liver 
and muscle and excursive hepatic glucose output. 
The hepatic glucose output is the principal factor for fasting hyperglycaemia and the 
postprandial hyperglycaemia is largely determined by the peripheral glucose 
utilization (Insulin Resistance) 
Insulin Résistance as a Primary defect : 
In type 2 DM, excretive production of glucose in the liver and under – utilisation of 
glucose in skeletal muscle is mainly due to the resistance to the action of insulin. 
Obesity is the powerful amplifier of the insulin resistance and the primary cause is 
unclear. Central obesity may have a particularly potent influence on insulin sensitivity 
in the liver and there by adversely affect hepatic gluconeogenesis and lipid 
metabolism. Many cross sectional studies have shown that the insulin resistance is the 
inherited defect that initiates the diabetic event. The hyperglycaemia to insulin 
resistance occurs in three places such as first phase: Plasma glucose remains normal 
despite demonstrable insulin resistance because the insulin levels are increased. 
Second Phase: Insulin resistance tends to worker so that postprandial hyperglycemias 
develop despite elevated insulin concentration. Third phase: Insulin resistance close 
not change but declining insulin secretion caused fasting hyperglycaemia. 
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Because of insulin resistance, the beta cells produce excess insulin. As the 
resistance progresses the muscle glucose uptake becomes impaired, but the insulin 
produced is efficient to maintain the hepatic glucose output in the normal range 
eventually as hyperglycaemia becomes severe the compensatory hyperinsulinemia is 
no longer adequate to maintain the fasting plasma glucose normal level. The 
development of fasting and post – prandial hyperglycaemia stimulates the beta cell 
further. The resultant hyperinsulinemia leads to the down regulation of the receptor 
number and the post receptor events. This exacerbates the insulin resistance further 
resulting in chronic hyperglycaemia, which is toxic to the beta-cell and is responsible 
for the acquired defect of impaired insulin secretion. When the insulin becomes 
deficient, the „glucose transporter‟ system becomes severely impaired and the 
intracellular enzymatic steps involved in metabolism are depressed. 
 
Impaired pancreatic insulin Secretion. (Impaired beta cell function) 
The beta cell dysfunction in diabetes fall into two district types a) The pulsatile insulin 
delivery is lost even when the glucose is normal, b) The loss of compensatory 
mechanisms which include increased beta cell mass, Quantitative insulin output and 
maximum secretary Capacity. 
Normally insulin is secreted in a pulsatile fashion and also secreted in response to 
meals or secretagogues. The pulsatile secretion is called ultradian oscillations. The 
ultradian pulses of insulin secretion occur every 90 to 120mts and are exaggerated 
after the ingestion of food besides the ultradian pulsation rapid oscillations of insulin 
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level occur every 8 to 16mts in the beta cell. These rapid oscillatory insulin pulses are 
effective in inhibiting hepatic glucose output. 
 The insulin secretion following a glucose load shows a biphasic response. The 
first phase acute insulin response (AIR) is due to release of insulin stored in the 
granules, which suppresses the hepatic glucose output. This occurs within 4 to 5mts 
and returns to normal within 10mts. The second phase is in response to the ambers rise 
in the glucose level, which promotes disposal of glucose in peripheral tissue. In type 2 
Dm subjects the ultiadian oscillation of insulin delivery is no longer present and the 
first phase of insulin release is lost. 
Beta cell dysfunction 
  In the early stages of type 2 diabetes, there is only moderate reduction in 
the total mass of pancreatic islet tissue. The Beta cell mass is mildly reduced 
especially when obesity is taken into account. Amyloidal deposits are frequently 
observed in the islets. Morphologicallyislets appear normal and insulitis is never 
present. Amylin or the islet amyloidal polypeptide is a 37 amino acid protein normally 
produced by the beta cells and co-packaged with insulin in the secretary granules and 
co-secreted in the sinusoidal space. For reasons unknown this material tends to get 
accumulated extracellularly in close contact with beta cells and forms fibrils. Amylin 
has been reported to lower basal and insulin stimulated glycogen synthetase in the 
muscles and to inhibit glucose stimulated insulin secretion. These abnormalities of 
deficient insulin secretion and insulin action are similar to the pathogenic factors of 
type 2 DM. 
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Insulin secretary abnormalities in type 2 Diabetes mellitus: 
Mainly there are decreased glucose sensing, impaired ability to respond to 
elevations and reductions during glucose infusion, reduced or absence first phase 
insulin secretion in response to intravenous glucose administration, reduced or 
absence early insulin secretary response to oral glucose, alterations in the rapid 
oscillations of insulin secretion, reduced effect of gastrointestinal hormones in 
potentiating glucose mediated insulin secretion and inadequate insulin secretion for 
the magnitude of hyperglycemia 
[7] 
. 
 
 
Progression to type2 diabetes 
 
Genes 
Obesity, β-cell capacity, insulin resistance, other 
 
    + 
 
Environment inactivity/abundant food 
 
Beta cell decompensation impaired glucose tolerance 
Decline of β-cell mass 
Severe hyperglycemia 
hypoinsulinemia 
glucotoxicity 
lipotoxicity 
   Type2 diabetes                  
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Diagnosis criteria of diabetes:- 
Diagnosis of diabetes is based on the glucose level in the body. This is 
evaluated by doing proper blood investigations such as Random blood sugar level 
(more than 200gms %) or fasting plasma glucose level (more than 126mgs %). When 
in doubt; a standard glucose tolerance test is used to diagnose diabetes mellitus. 
Impaired fasting glucose and impaired glucose tolerance acts as a tool for the 
diagnosis of diabetes mellitus oral glucose tolerance test is the only diagnostic test for 
diagnosing impaired glucose tolerance. 
OGTT: 
This test is done in the morning following 10-16 hrs of overnight fast with 
unrestricted diet for at least three days. This is done to sensitize the beta cells of 
pancreas. During the test only, water is given to alleviate the thirst.  
Procedure: 
Fasting blood sample is collected before giving glucose to the patient. Then 75gms of 
glucose in 250ml of water is given. Again blood sample is collected 2hrs after the 
loading dose. Blood sample are collected in tubes containing fluoride- oxalate, to 
prevent the red blood cells from metabolizing glucose. 
WHO guidelines of oral glucose tolerance test for diagnosing diabetes mellitus. 
2hrs after the loading dose →   > 200mg/dl 
Impaired glucose tolerance  
(2hrs after 75gm glucose load)                 → 140 to 199 mg/dl 
 
Normal Blood glucose value indicating patient is nondiabetic:  
Fasting                                     → < 100 mg/dl 
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2hr after 75gm load                 → < 140 mg/dl 
 
Diagnostic criteria: 
Glucose tolerance is normal when the fasting and the 2hr values are < 100mg and < 
140mg respectively. Diabetes is diagnosed when the fasting value is >126 mg or 2 hr 
plasma glucose is >200mg. IGT is present when the two –hour value is in the range of 
140 to 199mg/dl. IFG is present when the fasting level is >100 and < 125mg/dl and 
the two hour value is < 140mg/dl  
[1] 
. 
Glycosylated Hemoglobin: 
Glucose is bound to hemoglobin irreversibly by a continuous slow non-enzymatic 
process resulting in the formation of glycosylated hemoglobin. The amount of adult 
hemoglobin that becomes glycosylated to form HbA1C is directly related to average 
concentration of glucose in the blood. In a normal person about 3 to 6% of Hb is 
glycosylated. In a diabetic the percentage of HbA1C may double or even triple. It has 
got the advantage of not influenced by diet, mode of therapy, physical activity. 
Normal value: Below 6%, Good control: 6% – 7%, Fair control: 7% - 8%, 
Unsatisfactory control: 8% - 10%, Poor control: above 10% 
[1] 
. 
Goals of therapy in diabetes: 
Glycemic control HbA1C < 7.0%, Preprandial capillary plasma glucose   3.9-
7.2mmol/L(70-130mg/dl), Peak postprandial capillary plasma glucose 10.0 mmol 
/L(<180mg/dl), Blood pressure <130/80 mmHg, Lipids: LDL <2.6 mmol 
/L(<100mg/dl), HDL >1.1 mmol /L (>40mg/dl), Triglycerides 
<1.7mmol/L(<150mg/dl). 
[8]
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Periodic Assessment for Patients with Diabetes 
Self-monitoring of blood glucose (SMBG), HbA1C testing (2-4 times/year), patient 
education in diabetes management (annual), medical nutrition therapy and education 
(annual), eye examination (annual), foot examination (1-2 times/year by physician; 
daily by patient), screening for diabetic nephropathy(annual), blood pressure 
measurement(quarterly), lipid profile and serum creatinine (estimate GFR) (annual). 
Other management such as Influenza/pneumococcal immunizations and antiplatelet 
therapy should be initiated. 
 
Treatment of Diabetes mellitus:- 
Non pharmacological Management (Life –style modification) such as 
education, nutrition and exercise. Diabetic Education such as Diabetic Educator 
(Nurse , dietician, Pharmacist ) to ensure that patient know about diabetic diet, self-
monitoring of blood glucose, self-administration of insulin, management of 
hypoglycemia and management of complications and risk factors modifying agents. 
Nutrition foot such as Fat 20-35% of total caloric intake, saturated fat <7% of total 
calories,  <200mg/day of dietary cholesterol, two or more servings of fish/week 
provide ω-3 polyunsaturated fatty acids. Carbohydrate diet should contain 45-65% 
total caloric intake (low-carbohydrate diets are not recommended), amount and type of 
carbohydrate are important, sucrose-containing foods may be consumed with 
adjustments in insulin dose. Protein intake must be 10-35% of total caloric intake 
(high-protein diets are not recommended), fiber-containing foods may reduce 
postprandial glucose excursions and non-nutrient sweeteners.  
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Exercise has been recommended as an important adjuvant in the management 
of diabetes mellitus. The exercise response in a diabetic patient largely depends upon 
the diabetic status, blood sugar level, availability of insulin and state of hydration etc. 
Benefits of exercise in type 2DM are substantial. It has got beneficial effects on 
cardiovascular risk factors, blood pressure. Yoga has got specific role in the treatment 
of diabetes mellitus. This results in an increase in maximal oxygen uptake, decrement 
of submaximal heart rate and an augmentation of stroke volume. There are studies 
showing that practice of pranayama in normal healthy individuals produces a 
significant fall in the fasting blood sugar and postprandial sugar. Yoga in diabetic 
patient results in metabolic changes such as reduction in lipid profile (decreases LDL-
CH and increases HDL – cholesterol). 
Pharmacological management of Diabetes Mellitus: 
Pharmacological management includes oral hypoglycaemic agents and insulin 
therapy. Oral hypoglycaemic agents are predominantly indicated for the treatment of 
Type II DM. Oral hypoglycemic agents are defined as the drugs that are used to lower 
blood glucose levels and are effective orally. Hypoglycemic drugs approved by FDA 
and available in the market are 1. Sulfonylureas 2. Biguanides 3. Meglitinide 
Phenylalanine analogues (4) Glucagon like peptide -1(GLP-1) agonist (5) 
Thiazolidinediones (6) α-Glucosidase inhibitors. Newer drugs have been invented due 
to certain limitations (weight gain, hypoglycemic, increased cardiovascular motality) 
and loss of efficacy of already existing drugs. One among them is DPP-4 inhibitors 
invented in 2005 in Japan. Other novel drugs are Dopamine –D2 receptor agonist and 
sodium –glucose cotransport-2 (SGLT-2) inhibitor. 
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Drugs used in this study are Sulfonyurea, Biguanides, DPP-4 inhibitors such as 
Sitagliptin and Vildagliptin. Sulfonyulureas are otherwise called as insulin 
secretagoues. These drugs are available in the market since 1970 as First generation – 
Tolbutamide, Second generation - Glibenclamide, Glipizide, Gliclazide and 
Glimepride. 
 
Sulfonyl ureas: 
The mechanism of Sulfonyl ureas act by increasing the insulin release from the 
pancreas. Two other actions are reduction of serum glucagon levels and closure of 
potassium channels in extra pancreatic tissue. Sulfonyl ureas bind to a (140-KD 
receptor) specific receptor associated with a beta-cell inward rectifier ATP-sensitive 
potassium channel. After binding to the receptor, it inhibits the efflux of potassium 
ions through the channel and results in depolarization. As a result of depolarization, 
voltage –gated calcium channel is opened and calcium is released into the cell. Influx 
of calcium into the cell stimulates the insulin release from the pancreas 
[9]
. 
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SU are well absorbed orally 90% bound to plasma proteins. The total volume 
of distribution is about 0.2 to 0.4 L/Kg. They are preliminary metabolized into active 
metabolites and excreted in urine. Adverse effects are hypoglycemia, weight gain due 
to insulinaemic action, nausea, vomiting, flatulence, diarrhoea or constipation, 
headache and parestherias are generally mild and infrequent. Hypersensitivity 
reactions such as rashes, photosensitivity, purpura, transient leucopenia, rarely 
agranulocytosis may occur. Flushing and disulfirm – like reaction after alcohol is 
reported in individuals consuming sulfonylurea 
[10].
Drugs such as salicylates, 
Ketoconazole, sulfonamides, Warfarin, and chloramphenicol enhance action of 
Sulphonylureas phenobarbitone, phenytoin, rifampicin decrease the action of 
Sulphonylureas 
[10].
 
 
Biguanides: (Phenformin, Metformin) 
Phenformin has been banned in India since 2003, because of higher risk of 
lactic acidosis. Metformin is available since 1950s. 
The metformin mechanism of action is otherwise called as insulin sensitizes. 
They are used to overcome the insulin resistance. They exert their action on both 
carbohydrates and lipid metabolism. It is highly effective in obese type 2 DM patients 
and is also synergistic in combination. The primary effect is to reduce the hepatic 
glucose production through activation of the enzymes AMP – activated protein kinase 
(AMPK). This action is responsible for leaving of blood glucose in diabetics. 
Impairment of renal gluconeogenesis, slowing of glucose absorption from the 
gastrointestinal tract, with increased glucose to lactate conversion by enterocytes, 
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direct stimulation of glycolysis in tissue, increased glucose removal from blood, 
reduction of plasma glucagon levels and reduced lipogenesis in adipose tissue and 
enhanced fatty acid oxidation 
[9].
 
 
 
The plasma t ½ of Metformin is 1-3 hrs. Duration of action is 6 to 8 hrs. It is 
used as a first line of drug in the management of type 2 diabetes mellitus. The 
advantages of the drug are Non hypoglycemia, weight loss promoting, has potential to 
prevented macro vascular as well as micro vascular complications of diabetes, no 
acceleration of β cell exhaustion /failure in type 2 DM , anti hyperglycemic efficacy 
(HbA1C reduction by 0.8 to 1.2 %), can be used as mono therapy or combined therapy 
with other oral hypoglycemic agents when one drug is not adequate. It is used to treat 
obese patients with type 2 DM, the other uses are dumping syndrome, 
hyperprolactinaemia, polycystic ovarian disease. It is contraindicated in hypotensive 
states, heart failure, severe respiratory, hepatic and renal disease.  
The Adverse effect are abdominal pain, nausea, bloating, metallic taste, mild 
diarrhoea. In case of renal failure, it accumulates inside and results in the increased 
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risk of lactic acidosis. Vitamin B12 deficiency occurs due to interference with its 
absorption. Cimetidines, Furosemide compete with Metformin excretion and enhance 
its toxicity. 
DIPEPTIDYL PEPTIDASE-4 INHIBITOR 
 
The incretin effect of GIP in stimulating insulin secretion is almost lost in 
T2DM and many studies indicate the existence of a specific defect in GIP action in 
these patients, may be due to chronic desensitization of GIPRs (Glucose dependent 
insulinotropic peptide receptors) 
[11].
 The defect in the incretin hormone response leads 
to the discovery of incretin based therapy. They are GLP-1 Agonist and DPP4i 
[12].
 
DPP4 inhibitors are proved to have good therapeutic effect in the treatment of type2 
DM. They act by enhancing the action of incretin hormones.It inhibits the inactivation 
of incretin hormones by DPP4 enzyme. Incretins seems to play a major role in the 
regulation of glucose metabolism in healthy subjects. There are six DPP-4 inhibitors 
available in the market. They are sitagliptin, vildagliptin, saxagliptin, alogliptin, 
linagliptin and teneligliptin. 
Sitagliptin was the first of the DPP-4i to be approved by the US Food and Drug 
Administration in 2006. This was followed by the approval of vildagliptin in February 
2007.  Recently, saxagliptin in 2009 and alogliptin in 2010 (presently only in Japan). 
Compounds such as sitagliptin (β-amino acid based) and vildagliptin which are nitrile 
containing inhibitors 
[3].
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PATHOGENESIS AND PATHOPHYSIOLOGY OF TYPE 2 DIABETES 
MELLITUS: 
 
 
 
 Gastrointestinal hormones are hormones that are secreted immediately 
following a meal. These hormones regulate the gut motility, gastric acid secretion, 
pancreatic enzymes, contraction of gall bladder and absorption of nutrients. One 
among them is incretin hormones. Following a meal there is an increase in the level of 
glucose, which stimulates the release of incretin hormones. There are two incretin 
hormones secreted in the body.  They are glucose dependent insulinotropic 
polypeptide (GIP) and Glucagon like peptide – 1 (GLP-1). GIP is secreted first, and it 
has got potent insulinotropic action. It is a 42 – amino acid hormone produced in 
duodenal and jejunal endocrine K cells in the proximal small bowel. GLP – 1 was 
produced second following cloning of the cDNA‟s and genes encoding proglucagon.  
The GIP receptors are present on islet α and β cells and in peripheral tissues including 
central nervous system heart, kidney, lung and gastrointestinal tract 
[13].
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When these hormones are released, the incretin receptor present on the β cells are 
activated resulting in the rapid increase of insulin level by process called exocytosis. 
GLP – 1 acts on the pancreatic β cells and induces the secretion of insulin and reduces 
the secretion of glucagon from the pancreatic α – cells. GLP – 1 improves the β – cell 
function and delays gastric emptying. It promotes glucose disposal through neural 
mechanism which contribute to the control of glucoregulation.  The action of GLP – 1 
and GIP are affected by enzymatic inactivation due to dipeptidyl peptidase 4 enzyme.  
             DPP – 4 enzyme is an aminopeptidase with a membrane spanning cell 
– surface. It is present in many tissues such as liver, lung, kidney, intestinal blush 
borders membranes, lymphocytes and endothelial cells. The DPP – 4 enzyme is 
cleaved from its anchored – membrane at the extracellular domain and it retains its 
enzymatic activity while circulating in the plasma. DPP – 4 cleaves mainly peptides 
with proline or alanine residue present in the second position of amino terminal. 
Neuropeptides, cytokines, chemokines are substrates of DPP-4 enzyme. GLP – 1 and 
GIP are one among of them 
[14].
  
It has been discovered that there is a defective response of incretin hormones 
leading increase in glucose level in to type 2 Diabetes mellitus. The incretin effect of 
GIP hormone is lost in Type 2DM, mainly due to chronic desensitization of GIPRS 
[15].
 Hence the results in the development of newer therapy called incretin based 
therapy. There are two class of drugs involved in Incretin base therapy known as GLP 
– 1 agonist and DPP – 4 inhibitors. DPP – 4 inhibitors inhibit the action of DPP-4 
enzymes, which degrades the circulating GLP – 1. DPP – 4 inhibitors was first 
approved by FDA in 2005 in Japan. They reduce 80% of the DPP – 4 enzyme activity, 
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within 24 hr of administration. They have established a new therapeutic approach in 
the treatment of Type 2 diabetes mellitus. Currently available DPP – 4 inhibtors are 
Sitagliptin, Vildagliptin, saxagliptin, alopgliptin, linagliptin and tenegliptin. DPP- 4 
inhibitory action increases the circulating levels of GLP – 1 and GIP three times 
higher than the normal thereby it increases the secretion of insulin from the pancreatic 
β cells and decreases the secretion  of glucagon from the panereatic α – cells.  
 
Sitagliptin phosphate: 
 
 
Pharmacokinetics:  
 Sitagliptin ( Sitagliptin phosphate ) , β – amino acid based compound was the 
first DPP – 4 inhibitor invented in 2006. The absorption of Sitagliptin is rapid and oral 
bio availability is about 87% 
[16]
 . The inhibitory action starts immediately within 5mts 
following oral administration. The total volume of distribution is about 198L which is 
higher than the total body water.  These inhibitors have very low plasma protein 
binding effect and it is about 38% 
[17].
 Sitagliptin doesn‟t undergo proper metabolism. 
They are excreted as parent compound (About 80%) and the rest is metabolised via 
cytochrome CYP3A4 and CYP2C8. Active transport such as organic anion transporter 
(OAT) – 3, organic anion transporting polypeptide (OATP) – 4 CI and PGP 
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transporters in the proximal tubule are responsible for the excretion  of 30% of the 
compound 
[18].
 It has got good inhibitory effect and forms non – covalent interactions 
with residues in the catalytic site 
[19].
 Sitagliptin, have no specific drug interactions. 
They are neither enzyme inducers or inhibitors 
[20].
  
Safety and efficacy : 
Sitagliptin has got better safety and efficacy when compared with other oral 
hypoglycalmic agents.it significantly reduces fasting plasma fasting glucose level, 
postprandial plasma glucose level and glycolsylated haemoglobin (Hba1c)in type 
2DMpatients .with a dose 100mgonce daily. Sitagliptin can be used with dose 
adjustment in type 2DM patients with renal insufficiency, based on the creatinine 
clearance .It can be used without adjusting the dose in mild renal insufficiency 
[creatinine clearance (CrCl) 50–80 ml/min] In moderate (CrCl 30–50 ml/min) or 
severe renal insufficiency/ end-stage renal disease (ESRD) (CrCl<30 ml/min) , the 
dose is  adjusted to 50 and 75%, respectively 
[21].
 There is no need for dose alteration 
in  hepatic  insufficiency  patients . there is no significant alteration in the enzyme 
levels when treated with sitagliptin in type 2DM patient with hepatic impairment 
[22].
 
It does not cross the blood brain barrier but crosses the placenta freely so, they are not 
indicated during the pregnancy and lactation period 
[17]
.    
Adverse Effects: 
Naropharyngitis, urinary tract infections, pancreatitis, head ache, allergic reactions 
such as angioedema and exfoliative dermatological reactions. 
Contraindications: 
Acute pancreatitis, pancreatic cancer 
[23].
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Trials with Sitagliptin: 
Monotherapy: 
Many trials have been done with sitagliptin as a monotherapy in type 2  DM 
patients.In a study done by Ascher, after 24 weeks therapy with sitagliptin 100 and 
200 mg,it has reduced FPG,PPG and HBA1C levels significantly (p<0.001) when 
compared with placebo 
[24].
 In other study organized by Raz and groups, sitagliptin 
100mg and 200mg once daily with the study period of 18 weeks,it significantly 
showed decrease in HBA1C of in patients with 100mg and 200mg respectively. When 
compared with placebo with significant(p<0.001).There was less hypoglycaemic 
symptoms recorded compared to placebo and weight was maintained neutrally with 
the patients treated with sitagliptin. In this study DPP-4 activity is inhibited by >80% 
with the 2-fold rise in active GLP-1 levels 
[25].
 Type 2 DM with coronary artery 
disease, when treated with sitagliptin, it was found sitagliptin improves their heart 
function and coronary artery perfusion, which was confirmed and evaluated by doing 
echo-debutamin test 
[26].
 Recently, in a study done in metabolic syndrome patients 
with type 2 DM, it has showed that sitagliptin minimally reduces the blood pressure 
(both systolic and diastolic) during the study period 
[27].
 
Combined therapy: 
In a study done in 353 patients with uncontrolled hyperglycemia with pioglitazone, 
after 24 weeks of treatment with an add on therapy showed a very good reduction in 
HBA1C of 0.7% (p<0.01) and FPG of 17.7mg/dl (p<0.001) with low hypoglycaemic 
symptoms 
[28]
. A study conducted by ottavio and colleagues, 31 insulin treated patients 
with inadequate glucose level was treated with sitagliptin for a period of 21 weeks. 
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After 21 weeks there was a significant reduction in fasting plasma glucose, PPG, 
HBA1C and it reduces the daily insulin requirement and improved the metabolic 
control by reducing the low density cholesterol level 
[29]
. Cherbonnel conducted a 
study with 701 patient who had inadequate glycaemic control with metformin. 
Sitagliptin 100mg once daily was given to the patients and fasting glucose level, 
postprandial glucose level and HBA1C was evaluated after a period of 12 weeks. It 
was found that sitagliptin has reduced HBA1C, FPG and PPG level significantly and 
achieved the ADA glycaemic goal of HBA1C of <7% when compared with placebo 
treated patients 
[30].
 
                     In a study organized by Nauck and colleagues, after 52 weeks therapy 
with sitagliptin 100mg once daily along with Glipizide 20mg once daily, it was found 
that sitagliptin significantly achieved HBA1C reduction of 0.67% and weight loss was 
found in patients with combined therapy when compared to small weight gain in 
patients treated with glipizide alone 
[31].
 
                    Goldstein demonstrated a study in type 2 DM patient to know about the 
effect of sitagliptin as a monotherapy and combined therapy with metformin. It was 
found that all treated groups showed proper reduction in FPG, PPG levels and 
HBA1C levels compared to placebo and add on therapy is more effective than the 
monotherapy 
[32].
  
VILDAGLIPTIN 
 
Vildagliptin is the second DPP-4 inhibitor approved for human use and is indicated 
for the control of hyperglycemia in patients with type 2 DM. Vildagliptin produces 
sustained inhibition of DPP-4 when administered and produces moderate increases in 
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GLP-1 and GIP circulating levels. Vildagliptin is available as 50 mg and 100 mg 
tablets with a recommended dose of 50 mg once daily if used in combination with 
metformin or a TZD and 50 mg once daily if used in combination with a sulfonylurea. 
Vidagliptin, a second DPP-4 inhibitor was invented and approved by FDA in February 
2007. Gliptins show good glycemic control and are well tolerated, particularly with 
regard to weight change and hypoglycemia. 
 
 
Vildagliptin ((S)-1-[N-(3-hydroxy-1-adamantyl) glycyl] pyrrolidine-2-carbonitrile) 
chemical formula 
 
Pharmacokinetics: 
The total volume of distribution of vildagliptin is about 70L which is greater than the 
total body water 
[33].
 They have very low protein binding capacity (10%). Vildagliptin 
are well absorbed orally and have good bioavailability of 85% 
[34]
 . Vildagliptin is 
metabolized in the liver via CYP450 isoenzymes into carboxylic acid metabolite 
(M20.7/LAY 151) and four minor metabolites. 50% of the parent compound is 
converted into active metabolites and 22% of the dose administered is excreted 
unchaged in the urine and active transportes are involved in the elimination in addition 
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to glomerular filtration 
[35].
 Vildagliptin is cleared from the plasma quickly and it has 
very rapid onset of action 
[33]. 
The inhibitory effect is carried out as a two step process, 
which includes formation of reversible covalent enzyme inhibitor complex. This 
complex has got slow rate of inhibitor binding and inhibitor dissociation, equilibrates 
the active and in active forms 
[36]. 
By this action, it means that the catalytic activity 
will be inhibited even after the drug has been cleared from the circulation vildagliptin 
is a potent inhibitor of DPP-4 enzyme. The concentration required to exert inhibitory 
action is about 50% 
 [33].
 It does not have interaction with the substrates of CYP 450 
isoenzymes. It has a long dissociation half –life (1hr) from DPP-4, when compared to 
the other competitive inhibitors 
[37].
 They are neither inhibitors nor induce. There is no 
pharmacokinetic interaction has been found between viladagliptin and metformin, 
Piogliltazone or glibenclamide 
[38].
 
Monotherapy: 
In a study organized to assess the effect of vildagliptin 100mg once daily on glycemic 
control plasma glucagon and insulin levels, following 4 week treatment, it showed that 
vildagliptin significantly reduced fasting glucose and postprandial glucose 
level(P<0.037 and P<0.001 respectively) also HbA1C by 0.38% (P<0.001) Vs 
placebo. There were no symptoms of hypoglycemia during the study period. Glucagon 
levels were reduced and there was no alteration found in the insulin levels. In this 
study author finally concluded that vildagliptin improves the metabolic control and by 
reducing the glucagon levels 
[39].
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One study done in few patients with type 2DM, who were treated with vildagliptin 
50mg and 100mg once daily showed an effective decrease in HbA1C 0.43%(P=0.003) 
and 0.40% (P=0.004) respectively, positive decrease in PPG levels was seen in 
patients treated with vildagliptin 50mg once daily. Hypoglycemic events among the 
treated groups are very less and had a weight neutralizing effect throughout the study 
[40].
 
In a group of patients with T2DM, when treated with vildagliptin 50mg once daily 
over a period 24 weeks, who was not on prior treatment with other oral 
hypoglycaemic drugs, it showed an average decrease in HbA1C levels by 1.4%. A 
study demonstrated that after 4 weeks therapy in drug naïve type 2 DM patients with 
vildagliptin, it significantly improved the postprandial plasma triglyceride level and 
apolipo protein (B-48), containing triglyceride –rich lipoprotein particle metabolism. 
The main mechanism behind is the pharmacological inhibition of GLP-1 receptor 
(GLP-1R) signaling, reduces, intestinal secretion of triacylglycerol, cholesterol and 
apolipoprotein B-48 
[41].
 
One study done is Japanese people around 291  type 2DM patients, proved that after 
12 weeks treatment with vildagliptin 10mg, 25mg, 50mg bd presented, Significant 
reduction in HbA1C levels by 0.53%, 0.67% and 0.92% respectively (P<0.001 Vs 
Placebo) with the baseline level of 7.4% 
[42].
  
In an another study conducted among type 2DM patients treated with vildagliptin with 
different doses such as 50mg bd and 50mg od over a period of 24 weeks, showed a 
significant decrease in mean FPG levels in both the groups compared to placebo. Total 
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of 1135 patients treated with vildagliptin 50mg bd indicated a significant (P<0.05) 
reduction of mean fasting plasma glucose of 1.08 mmol/L from mean baseline FPG of 
10.3 mmol/L after 24 weeks therapy 
[43].
 
A double blind randomized trial study was done in type 2 DM patients (N=786 with 
baseline HbA1C 8.7%) to compare the efficacy of vildagliptin with rosiglitazone 8 
mg once daily.    
Vildaglipting 100mg once daily was given over a 24 week period. After 24 week 
therapy, it has been noticed that vildagliptin significantly decreased HbA1C levels 
from the baseline and proved that vildagliptin is not inferior to rosiglitazone. Some 
patient treated with rosiglitazone showed side effects such as oedema and increase in 
body weight whereas such complaints were not reported by patient treated with 
vildagliptin 
[44].
     
Combined therapy: 
In a randomized study done in 592 type 2 DM patients with uncontrolled 
hyperglycemia, who were treated with pioglitazone 30mg once daily (groupI), 
vildagliptin 100mg once daily (Group II), vildagliptin 100mg once daily plus 
pioglitazone 30mg once daily, (Group III), showed that group III patients treated with 
(vildagliptin 100mg once daily plus pioglitazone 30mg once daily) had satistically 
significant reduction in HbA1C levels. Compared to patients treated with pioglitazone 
alone (1.9% Vs 1.4% P<0.001) 
[45].
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Another randomized trials done in 256 patients with type II DM who were on insulin 
therapy, addition of vildagliptin 50mg twice daily over a period 24 weeks showed a 
effective decrease in HbA1C by 0.5% to 0.1% in the vildagliptin group patients 
compared to 0.2% to 0.1% in the placebo group (P=0.022). There was only minimal 
hypoglycemic effect reported by patients treated with vildagliptin compared to 
placebo 
[46].
 
In a study organized by Galiant and colleagues, efficacy and tolerability of 
vildagliptin is compared with thiazolidinediones in T2DM patients with in adequate 
glycemic control over a study period of 3 months. After three months it was found that 
vildagliptin treated group has got good HbA1C reduction from the baseline compared 
to the TZD treated patients. It has been proved that vildagliptin is not inferior to TZD 
[47].
 
Special patient population: 
In a double blind randomized active – controlled study done in 335 drug naive patients 
with type 2 DM aged around 65 yrs, showed that vildagliptin is an effective and well 
tolerable by elderly people. In this study 42% of patients has normal renal function, 
57% had mild renal insufficiency and less than 2% had moderate renal insufficiency. 
Out of which study has resulted that vildagliptin has got good safety and efficacy in 
elderly people with type 2 DM without dose adjustment. Exposure to vildagliptin 
increase by 2-fold in elderly people and it does not have any relation with the severity 
of renal impairment. The lack of clear correlation between increased exposure and 
renal impairment contributes to both the excretion and hydrolysis metabolism of 
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vildagliptin. DPP-4 inhibitors can be used in patients with mild, moderate and severe 
or end stage renal insufficiency. With dose adjustments vildagliptin can be used for 
the treatment of T2DM with renal impairment base on the creatinine clearance 
[48].
   
Safety Profile: 
A study done as per FDA US guidance, demonstrated that vildagliptin is safer among 
elderly people and have got good efficacy with dose of 50mg twice daily. Vildagliptin 
reduces the triglycerides absorption from the gut and there by the reduces the high 
plasma triglyceride concentration, increases HDL cholesterol concentration and 
decreases the LDL cholesterol concentration. This promotes lipid mobilization and 
catabolism in the post absorptive state. Vildagliptin does not cross the blood brain 
barrier and prevents cardio and cerebro vascular events in Type 2DM patients. It 
crosses the placenta freely and it is advisable for treatment in pregnant and lactating 
mother with diabetes 
[49].
 A meta analysis conducted with pooled data to evaluate the 
efficacy of vildagliptin in hepatic impairment patients, showed that there was no 
elevation of the liver enzymes in vildagliptin treated patients. As a result, there is no 
need for dose adjustment of vildagliptin in type 2 DM with hepatic insuffiency 
[50].
 
          A double blinded controlled trial done in type 2 DM patients demonstrated that 
treatment with vildagliptin 50mg bd does not have any pancreatic related adverse 
effects such as use in sr. amylase level and abdominal pain. Vildagliptin has got less 
hypoglycemic symptoms and many studies results (vildagliptin as monotherapy 
compared to metformin and rosiglitazone) have substantiated this statement. Another 
monotherapy study showed that patients treated with metformin had higher incidence 
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of gastrointestinal side effects such as nausea, abdominal pain, diarrhea, dyspepsia and 
flatulence compared to the patients treated with vildagliptin 
[51].
    
MATERIALS AND METHODS: 
Study centre:  
The study was conducted after obtaining institutional ethical clearance from 
institutional ethical committee (IEC), Research cell of Chennai Medical College 
Hospital and Research Centre (Affiliated to the Tamil Nadu Dr.MGR Medical 
University), Irungalur, Tiruchirappalli   (enclosed A) 
Study Period: 12 weeks (from June 2014 to July 2015). 
Drugs used in this study are Glibenclamide 5mg od, Metformin 500mg od, Sitagliptin 
100mg od, Vildagliptin 50mg bd 
Inclusion Criteria 
Previously diagnosed type 2 diabetes mellitus patient with the age group of 30 to 70 
years on either glibenclamide  and metformin for atleast 3 months with uncontrolled 
blood glucose levels. 
Exclusion Criteria 
Type 1 diabetes, Severe ketosis, Coma or reduced level of consciousness due to 
diabetes within the past 6 months, Pancreatitis, Severe infection, Pre and postsurgical 
patients , Severe traumatic patients, History of laparotomy, Chronic intestinal 
diseases, Pregnancy and possible pregnancy, Breast feeding, Moderate and severe 
renal dysfunction, Severe hepatic dysfunction, Insulin treatment, Treatment with anti-
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diabetic drugs other than sulfonylurea, History of hypersensitivity Patients under 
medication with hypolipidemic drugs. 
Methodology: 
The present study is a prospective single center parallel arm open label randomized 
control study to evaluate the comparative effect of sitagliptin and vildagliptin on 
plasma glucose level HbA1C and serum lipid profile in type 2 diabetes mellitus 
patients, in combination with biguanides or sulphonylureas during the study period of 
12 weeks. Total of 700 patients were screened out of which 180 patients fulfilled the 
inclusion and exclusion criteria. The study subjects were randomly divided into 6 
groups, each group consisting of 30 patients. Study subjects were enrolled after 
obtaining informed consent. The subjects in each group were treated as follows and 
continued without any changes in the treatment during the entire study period. 
Group No. of 
subjects 
Subject descriptions 
I 30 Type II diabetic patients on Glibenclamide 
(5mg OD) 
II 30 Type II diabetic patients on Glibenclamide 
(5mg) + Sitagliptin (100mg OD) 
III 30 Type II diabetic patients on Glibenclamide 
(5mg) + Vildagliptin (50mg BD) 
IV 30 Type II diabetic patients on Metformin 
(500mg OD) 
V 30 Type II diabetic patients on Metformin 
(500mg) + Sitagliptin (100mg OD) 
VI 30 Type II diabetic patients on Metformin 
(500mg)+ Vildagliptin (50mg BD) 
[OD – Once a day; BD – twice a day] 
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Clinical Assessment: 
All subjects were interviewed regarding family history, personal history, treatment 
history, past history before starting the study. Height, weight, age Gender, BMI were 
recorded for all the patient. Patients were advised to follow regular exercise and strict 
diet during the study period. 
Laboratory analysis : 
About 5ml of blood was collected at 0
th
 week, 4
th
 week, 8
th
 week and 12
th
 week of the 
study period. Blood was added with an appropriate anticoagulant before estimation.  
Blood Glucose estimation: 
Fasting plasma glucose was estimated after 8 hrs of overnight fast and post prandial 
plasma glucose was evaluated after 2 hrs following meal at 0
th
 week, 4
th
 week, 8
th
 
week and 12
th
 week of the study period. Blood sample was collected and glucose 
estimation was analyzed by GOD/POD(Glucose oxidase peroxidase) enzymatic 
method. 
Serum lipid profile estimation: 
Blood samples were collected and estimated for serum lipid profile after overnight 
fast. Total cholesterol was analyzed by cholesterol oxidase peroxidase method, low 
density lipoprotein and high density lipoprotein was analyzed by direct enzymatic 
method, triglycerides was analyzed by glycerol -3-phosphate oxidase method. 
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Estimation of glycosylated haemoglobin       
HBA1C was analyzed by high performance liquid chromatography method . 
Serum amylase was analyzed by enzymatic method. 
Blood urea was analyzed by urease method 
Serum creatinine was analyzed by Jaffe‟s method 
 
Statistical analysis:  
Statistics were analyzed by SPSS statistical software package before and after therapy. 
The results were tabulated and values were presented as mean (+ or -) and SD. 
student‟s paired „t‟ test P value of <0.001 was considered to be statistically significant. 
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RESULTS: 
 
Age Distribution of the Subjects: 
                The mean age of the study population are shown in table 1 and 2. Among 
the six groups, 51 to 60 years of age subjects were involved maximum in the study. 
The mean age of subjects in group I was 53.70 (+or-) 4.73 years. Group II was 
55.53(+or-) 6.1, group III was 52.73 (+or-) 5.3, group IV was 53.03 (+or-) 5.8 years, 
group V was 59.20 (+or-) 6.0 years and group VI was 56.73 (+or-) 7.4 years.  
 
Table 1: Age distribution of the study population  
 
Age group (in years) No. of subjects (n=180) Percentage (%) 
36 - 40 1 0.5 
41 – 45 12 6.7 
46 - 50 32 17.8 
51 - 55 44 24.4 
56 - 60 52 28.9 
61 - 65 29 16.2 
66 - 70 10 5.5 
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Table 2: Mean age of the study population according to treatment group  
 
 
Group Treatment Group 
Mean Age 
Std. Deviation 
Group I Gilbenclamide 53.70±4.735 
Group II Gilbenclamide + Sitagliptin 55.53±6.185 
Group III Gilbenclamide + Vildagliptin 52.73±5.336 
Group IV Metformin 53.03±5.846 
Group V Metformin + Sitagliptin 59.20±6.025 
Group VI Metformin + Vildagliptin 56.73±7.465 
 Total 55.16±6.338 
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Figure 1: Bar chart showing distribution of mean age of all 6 groups  
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Gender Distribution of the study population: 
              Gender Distribution of the study population is shown in table 3. The 
maximum number of male patients were from group VI the followed by group II. In 
the female gender distribution the maximum  patients were from group III and Group 
IV. 
 
Table 3: Gender distribution of the study population according to treatment 
group  
 
Age group Male (%) Female (%) Total (%) 
Group I 20 (66.7) 10 (33.3) 30 (100) 
Group II 17 (56.7) 13 (43.3) 30 (100) 
Group III 15 (50) 15 (50) 30 (100) 
Group IV 15 (50) 15 (50) 30 (100) 
Group V 17 (56.7) 13 (43.3) 30 (100) 
Group VI 19 (63.3) 11 (36.7) 30 (100) 
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Figure 2: Bar chart showing gender distribution of all 6 groups  
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Mean BMI of the study population: 
              Mean body mass index of subjects recruited in the study were shown in table 
4. Patients with maximum BMI were found in group VI (37.95) followed by group II 
and group I of value 36.62 and 34.84 respectively. 
 
Table 4: Mean BMI of the study population according to treatment group  
 
 
Group Treatment Group Mean ±Std. Deviation 
Group I Gilbenclamide 34.8465 ±4.28893 
Group II Gilbenclamide + Sitagliptin 36.6279±4.44404 
Group III Gilbenclamide + Vildagliptin 25.5049±3.65303 
Group IV Metformin 26.8354±3.93206 
Group V Metformin + Sitagliptin 25.1883±1.99595 
Group VI Metformin + Vildagliptin 37.9537±4.96245 
 Total 31.1594±6.70646 
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Figure 3: Bar chart showing mean BMI of all 6 groups  
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Effect on fasting blood glucose level 
 
 
Table 5: Mean fasting blood glucose of all groups 
 
 
 
 
 
 
 
 
 
 
Groups 
Fasting Blood Glucose (mg/dl) 
0 week 4  week 8 week 12  week 
Group I 165.90±12.834 146.30±11.173 132.60±16.126 119.13±23.780 
Group II 178.67±2.444 159.60±11.560 128.27±23.779 100.80±8.462 
Group III 145.70±16.011 126.90±9.083 113.03±7.122 99.53±5.643 
Group IV 146.77±20.139 120.17±11.733 101.87±6.892 83.57±7.398 
Group V 163.87±25.254 130.30±19.935 101.87±11.711 78.97±9.757 
Group VI 168.63±24.782 139.60±17.814 106.97±12.896 79.47±8.959 
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Table 6: Reduction of fasting blood sugar among the groups at after 4, 8 and 12 
weeks of therapy  
 
 
 
 
 
 
 
 
 
 
 
Group V subjects had significant reduction  (p<0.001) of fasting blood glucose 
after 4 weeks and 8 weeks while Group VI had a mean reduction of 89 mg% after 
the 12 weeks therapy higher than all the other groups. Gliptins and metformin 
combination achieved higher glycaemic control of fasting glucose than the gliptins 
and sulfonylurea combination. 
 
 
 
 
 
 
 
Groups  Fasting Blood Glucose (mg/dl)  
4  week 8 week 12  week 
Group I 19.60±10.653 33.30±16.748 46.77±25.113 
Group II 19.07±4.777 50.40±23.053 77.87±11.325 
Group III 18.80±11.090 32.67±12.944 46.17±14.015 
Group IV 26.60±18.957 44.90±19.099 63.20±19.150 
Group V 33.57±12.199 62.00±19.789 84.90±22.507 
Group VI 29.03±14.342 61.67±19.711 89.17±23.486 
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Table 7: Inter-group comparison of reduction of fasting blood sugar among the 
groups after 4 weeks of therapy  
 
 
Group comparison after 4 
weeks 
Mean difference in 
reduction of fasting 
blood glucose 
Group I vs Group II 0.533 
Group I vs Group III 0.800 
Group II vs Group III 0.267 
Group IV vs Group V 6.967 
Group IV vs Group VI 2.433 
Group V vs Group VI 4.533 
Group I vs Group IV 7.00 
Group II vs Group V 14.50 
Group III vs Group VI 10.233 
 
The mean difference in reduction of fasting blood glucose after 4 weeks between 
the groups was not statistically significant except for Group II vs Group V and 
Group III vs Group VI. Post-hoc tests confirm that Gliptins and metformin 
combination achieved higher glycaemic control of fasting glucose than the gliptins 
and sulfonylurea combination. 
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Table 8: Inter-group comparison of reduction of fasting blood sugar among the 
groups after 8 weeks of therapy  
 
Group comparison after 8 
weeks 
Mean difference in 
reduction of fasting blood 
glucose 
Group I vs Group II 17.10 
Group I vs Group III 0.633 
Group II vs Group III 17.73 
Group IV vs Group V 17.10 
Group IV vs Group VI 16.76 
Group V vs Group VI 0.333 
Group I vs Group IV 11.60 
Group II vs Group V 11.60 
Group III vs Group VI 29.00 
 
The mean difference in reduction of fasting blood glucose after 8 weeks between 
the groups was not statistically significant except for Group 1 vs 2, Group 2 vs 
Group 3, Group 4 vs 5, Group 4 vs 6, and Group 3 vs 6. Sitagliptin and 
sulfonylurea combination achieved higher glycaemic control of fasting glucose 
than the vildagliptin and sulfonylurea combination (Group 2 vs Group 3). 
Vildagliptin and metformin combination achieved higher glycaemic control of 
fasting glucose than the vildagliptin and sulfonylurea combination (Group 3 vs 6). 
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Table 9: Inter-group comparison of reduction of fasting blood sugar among the 
groups after 12 weeks of therapy  
Group comparison after 12 
weeks 
Mean difference in 
reduction of fasting 
blood glucose 
Group I vs Group II 31.10 
Group I vs Group III 0.600 
Group II vs Group III 31.70 
Group IV vs Group V 21.70 
Group IV vs Group VI 25.96 
Group V vs Group VI 4.267 
Group I vs Group IV 16.43 
Group II vs Group V 7.03 
Group III vs Group VI 43.00 
 
The mean difference in reduction of fasting blood glucose after 12 weeks between 
the groups was statistically significant (p<0.001) except for Group I vs Group III, 
Group V vs Group VI and Group II vs Group V. Sitagliptin and sulfonylurea 
combination achieved higher glycaemic control of fasting glucose than the 
vildagliptin and sulfonylurea combination (Group 2 vs Group 3). Vildagliptin and 
metformin combination achieved higher glycaemic control of fasting glucose than 
the vildagliptin and sulfonylurea combination (Group 3 vs 6). Dual drug therapy 
with gliptins was better than monotherapy with metformin or sulfonylurea. In 
monotherapy, metformin achieved higher fasting glucose reduction than 
sulfonylurea. 
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Figure 4: Reduction of fasting blood glucose of all 6 groups at various time 
intervals 
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Effect on postprandial blood glucose level 
 
 
Table 10: Mean postprandial blood glucose of all groups 
 
 
 
 
 
 
 
 
 
 
 
 
Groups 
postprandial  Blood Glucose (mg/dl) 
0 week  4  week 8 week 12  week 
Group I 188.43±14.383 162.20±12.277 146.73±14.157 136.30±15.614 
Group II 195.40±15.644 172.83±10.593 151.17±6.550 133.20±5.549 
Group III 248.90±50.498 197.60±45.477 158.20±28.974 121.70±13.742 
Group IV 201.60±23.440 164.97±8.524 141.63±13.161 128.17±10.596 
Group V 249.80±31.072 202.73±22.019 157.70±13.550 126.80±9.890 
Group VI 258.77±49.535 214.10±23.271 163.20±13.242 125.83±9.581 
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Table 11: Reduction of post-prandial blood sugar among the groups after 4, 8 
and 12 weeks of therapy  
 
 
 
 
 
 
 
 
 
 
 
Group V subjects had maximum reduction of post prandial glucose after 4 weeks 
while Group VI had a mean reduction of  95 at the end of 8 wk and 132 mg% after 
the 12 weeks therapy higher than all the other groups. Gliptins and metformin 
combination achieved higher glycaemic control of PPG than the gliptins and 
sulfonylurea combination. 
 
 
 
 
 
 
 
Groups 
Postprandial Blood Glucose (mg/dl) 
4  week 8 week 12  week 
Group I 26.23±8.541 41.70±15.018 52.13±16.968 
Group II 22.57±7.366 44.23±1.264 62.20±14.048 
Group III 51.30±22.908 90.70±33.715 127.20±42.087 
Group IV 36.63±16.130 59.97±19.352 73.43±20.358 
Group V 47.07±18.939 92.10±25.356 123.00±27.885 
Group VI 44.67±55.972 95.57±50.018 132.93±49.218 
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Table 12: Inter-group comparison of reduction of post-prandial blood sugar 
among the groups after 4 weeks of therapy  
 
 
Group comparison after 4 
weeks 
Mean difference in 
reduction of post-
prandial glucose 
Group I vs Group II 3.667 
Group I vs Group III 25.067 
Group II vs Group III 28.73 
Group IV vs Group V 10.43 
Group IV vs Group VI 8.03 
Group V vs Group VI 2.40 
Group I vs Group IV 10.40 
Group II vs Group V 24.50 
Group III vs Group VI 6.633 
 
The mean difference in reduction of post-prandial blood glucose after 4 weeks 
between the groups was not statistically significant except for Group I vs Group 
III, Group II vs Group III and Group II vs Group V. Vildagliptin and sulfonylurea 
combination achieved higher glycaemic control  of post-prandial glucose than the 
sitagliptin and sulfonylurea combination at 4 weeks (Group 2 vs Group 
3).Sitagliptin and metformin combination achieved higher glycaemic control of 
post-prandial glucose than the Sitagliptin and sulfonylurea combination (Group 2 
vs 5). 
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Table 13: Inter-group comparison of reduction of post-prandial blood sugar 
among the groups after 8 weeks of therapy  
 
Group comparison after 8 
weeks 
Mean difference in 
reduction of post-
prandial glucose 
Group I vs Group II 2.53 
Group I vs Group III 49.00 
Group II vs Group III 46.46 
Group IV vs Group V 32.13 
Group IV vs Group VI 35.60 
Group V vs Group VI 3.467 
Group I vs Group IV 18.26 
Group II vs Group V 47.86 
Group III vs Group VI 4.867 
 
The mean difference in reduction of post-prandial blood glucose after 8 weeks 
between the groups was not statistically significant except for Group I vs Group 
III, Group II vs Group III, Group IV vs Group V, Group IV vs Group VI and 
Group II vs Group V. Vildagliptin and sulfonylurea combination achieved higher 
glycaemic control (90 vs 44) of post-prandial glucose than the sitagliptin and 
sulfonylurea combination at 8 weeks (Group 2 vs Group 3).Sitagliptin and 
metformin combination achieved higher glycaemic control of post-prandial 
glucose than the Sitagliptin and sulfonylurea combination (Group 2 vs 5).Dual 
drug therapy with gliptins achieved higher post-prandial glycaemic control than 
monotherapy with metformin or sulfonylurea. 
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Table 14: Inter-group comparison of reduction of post-prandial blood sugar 
among the groups after 12 weeks of therapy 
  
Group comparison after 12 
weeks 
Mean difference in 
reduction of post-
prandial glucose 
Group I vs Group II 10.06 
Group I vs Group III 75.06 
Group II vs Group III 65.00 
Group IV vs Group V 49.56 
Group IV vs Group VI 59.50 
Group V vs Group VI 9.93 
Group I vs Group IV 21.30 
Group II vs Group V 60.80 
Group III vs Group VI 5.73 
 
The mean difference in reduction of post-prandial blood glucose after 12 weeks 
between the groups was statistically significant (p<0.001) except for Group I vs Group 
III, Group II vs Group III, Group IV vs Group V, Group IV vs Group VI and Group II 
vs Group V. Vildagliptin and sulfonylurea combination achieved higher glycaemic 
control (62 vs 127) of post-prandial glucose than the sitagliptin and sulfonylurea 
combination at 12 weeks (Group 2 vs Group. Sitagliptin and metformin combination 
achieved higher glycaemic control of post-prandial glucose than the Sitagliptin and 
sulfonylurea combination (Group 2 vs 5). Dual drug therapy with gliptins achieved 
higher post-prandial glycaemic control than monotherapy with metformin or 
sulfonylurea. 
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Figure 5: Reduction of post-prandial blood glucose of all 6 groups at 
various time intervals  
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Effect on HbA1C 
 
 
 
Table 15: Mean HbA1C of all groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Groups 
HbA1C Blood Glucose (%) 
0 week 12  week 
Group I 6.84±0.145 6.40±0.233 
Group II 6.86±0.229 6.34±0.192 
Group III 7.160±0.3635 6.210±0.2468 
Group IV 7.060±0.2554 6.413±0.3246 
Group V 7.617±0.3742 6.107±0.3542 
Group VI 7.487±0.3471 6.080±0.3718 
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Table 16: Reduction of HbA1C among the groups after 12 weeks of therapy  
 
 
Reduction of 
HbA1C 
Group 
Mean 
Std. Deviation 
After 12 weeks 
Group I 
0.440±0.2111 
Group II 
0.523±0.2161 
Group III 
0.950±0.2502 
Group IV 
0.647±0.2569 
Group V 
1.510±0.4147 
Group VI 
1.407±0.2970 
 
 
All the groups lowered the mean HbA1C levels after 12 weeks and this reduction 
of HbA1C levels after 12 weeks among the groups was statistically significant 
(p<0.001)  and was maximum in Group V (1.5%)(metformin and sitagliptin 
combination) and group 6 (1.4%) (metformin and vildagliptin combination).  
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Figure 6: Line diagram showing HbA1C of all 6 groups at various time 
intervals  
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Effect on serum lipid profile 
 
Table 17: Comparison of Total cholesterol values of the groups before therapy 
and after 12 weeks  
 
 
Group 
Treatment 
Duration 
Mean  
Std. Deviation 
Mean 
difference 
Group 1 
Baseline 179.23±14.395 
2.267 
12 weeks 176.97±13.675 
Group 2 
Baseline 186.80±5.910 
7.767 
12 weeks 179.03±5.720 
Group 3 
Baseline 175.27±10.302 
2.567 
12 weeks 172.70±9.289 
Group 4 
Baseline 171.53±9.104 
2.133 
12 weeks 169.40±9.004 
Group 5 
Baseline 178.33±14.274 
4.033 
12 weeks 174.30±12.731 
Group 6 
Baseline 180.3±9.585 
5.30 
12 weeks 175.0±8.894 
 
The mean total cholesterol levels were lowered by all the drug combinations and 
this reduction of total cholesterol levels after 12 weeks was statistically significant 
(p<0.001). Maximum reduction of total cholesterol levels after 12 weeks was 
observed in group 2 (Gilbenclamide and Sitagliptin combination) 
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Table 18: Reduction of total cholesterol among the groups after 12 weeks of 
therapy  
 
 
Reduction of total 
cholesterol 
Group 
Mean ± 
Std. Deviation 
After 12 weeks 
Group I 2.27±3.331 
Group II 7.77±2.128 
Group III 2.57±2.837 
Group IV 2.13±0.973 
Group V 4.03±6.145 
Group VI 5.30±2.938 
 
 
All the groups lowered the mean total cholesterol levels after 12 weeks and this 
reduction of total cholesterol levels after 12 weeks among the groups was 
statistically significant (p<0.001)  and was maximum in Group II (7.7mg%) 
(Gilbenclamide and sitagliptin combination) and group 6 (5.3 mg%) (metformin 
and vildagliptin combination).  
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Figure 7: Line diagram showing total cholesterol of all 6 groups at before 
and after therapy  
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Table 19: Comparison of triglyceride values of the groups before therapy and 
after 12 weeks  
 
 
Group 
Treatment 
Duration 
Mean triglyceride 
Std. Deviation 
Mean 
difference 
Group 1 
Baseline 134.10±7.522 
2.267 
12 weeks 131.83±7.557 
Group 2 
Baseline 140.40±5.210 
8.467 
12 weeks 131.93±4.941 
Group 3 
Baseline 132.37±10.35 
2.40 
12 weeks 129.97±10.45 
Group 4 
Baseline 131.80±5.215 
2.033 
12 weeks 129.77±4.987 
Group 5 
Baseline 145.93±12.05 
11.36 
12 weeks 134.57±10.89 
Group 6 
Baseline 141.83±13.39 
8.367 
12 weeks 133.47±12.48 
 
 
The mean triglyceride levels were lowered by all the drug combinations and this 
reduction of triglyceride levels after 12 weeks was statistically significant 
(p<0.001).Maximum reduction of triglyceride levels after 12 weeks was observed in 
group 5 (metformin and Sitagliptin combination) 
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Table 20: Reduction of triglycerides among the groups after 12 weeks of therapy  
 
 
Reduction of 
triglycerides 
Group 
Mean 
Std. Deviation 
After 12 weeks 
Group I 2.27±1.929 
Group II 
8.47±2.389 
Group III 2.40±2.848 
Group IV 
2.03±.809 
Group V 11.37±7.025 
Group VI 
8.37±5.611 
 
 
All the groups lowered the mean triglycerides levels after 12 weeks and this 
reduction of mean triglycerides levels after 12 weeks among the groups was 
statistically significant (p<0.001)  and was maximum in Group V (11.3 mg%) 
(metformin and sitagliptin combination) and group II (8.47 mg%) (Gilbenclamide 
and sitagliptin combination).  
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Figure 8: Line diagram showing triglyceride levels of all 6 groups at before 
and after therapy  
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Table 21: Comparison of LDL values of the groups before therapy and after 12 
weeks 
 
 
Group 
Treatment 
Duration 
Mean LDL 
Std. Deviation 
Mean 
difference 
Group 1 
Baseline 74.93±5.252 
2.50 
12 weeks 72.43±5.969 
Group 2 
Baseline 85.73±4.127 
10.43 
12 weeks 75.30±4.793 
Group 3 
Baseline 77.10±13.304 
10.13 
12 weeks 66.97±12.050 
Group 4 
Baseline 79.40±4.53 
1.90 
12 weeks 77.50±4.54 
Group 5 
Baseline 95.50±12.102 
17.267 
12 weeks 78.23±6.168 
Group 6 
Baseline 78.03±12.18 
10.63 
12 weeks 67.40±9.205 
 
 
The mean LDL cholesterol levels were lowered by all the drug combinations and 
this reduction of LDL cholesterol levels after 12 weeks was statistically significant 
(p<0.001).Maximum reduction of triglyceride levels after 12 weeks was observed 
in group 5 (metformin and Sitagliptin combination) 
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Figure 9: Line diagram showing LDL cholesterol levels of all 6 groups at 
before and after therapy  
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Table 22: Reduction of LDL cholesterol among the groups after 12 weeks of 
therapy  
 
 
Reduction of 
LDL cholesterol 
Group 
Mean 
Std. Deviation 
After 12 weeks 
Group I 2.50±1.717 
Group II 10.43±3.617 
Group III 10.13±4.191 
Group IV 1.90±0.845 
Group V 17.27±8.658 
Group VI 10.63±4.881 
 
 
All the groups lowered the mean LDL cholesterol levels after 12 weeks and this 
reduction of mean LDL cholesterol levels after 12 weeks among the groups was 
statistically significant (p<0.001) and was maximum in Group V (17.2 mg%) 
(metformin and sitagliptin combination) and group 6 (10.63 mg%) (metformin and 
vildagliptin combination). 
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Table 23: Comparison of HDL values of the groups before therapy and after 12 
weeks 
 
 
 
Group 
Treatment 
Duration 
Mean HDL 
Std. Deviation 
Mean 
difference 
Group 1 
Baseline 65.20±8.719 
-1.033 
12 weeks 66.23±8.784 
Group 2 
Baseline 41.73±6.716 
-17.50 
12 weeks 59.23±4.289 
Group 3 
Baseline 42.20±6065 
-1.20 
12 weeks 43.40±5.87 
Group 4 
Baseline 47.37±4.382 
-0.633 
12 weeks 48.00±4.480 
Group 5 
Baseline 54.63±7.753 
-7.83 
12 weeks 62.47±5.698 
Group 6 
Baseline 41.27±5.445 
-1.93 
12 weeks 43.20±4.582 
  
The mean HDL cholesterol levels were increased by all the drug combinations and 
this improvement in HDLs cholesterol levels after 12 weeks was statistically 
significant (p<0.001).Maximum increase of HDL levels after 12 weeks was 
observed in group 2 (Gilbenclamide and Sitagliptin combination) 
 
 
71 
 
 
 
Table 24: Improvement of HDL cholesterol among the groups after 12 weeks of 
therapy  
 
Improvement of 
HDL cholesterol 
Group 
Mean 
Std. Deviation 
After 12 weeks 
Group I 1.03±1.732 
Group II 17.50±5.865 
Group III 1.20±1.424 
Group IV 0.63±0.765 
Group V 7.83±6.623 
Group VI 1.93±1.552 
 
 
All the groups improved HDL cholesterol after 12 weeks and this rise in mean 
HDL cholesterol levels after 12 weeks among the groups was statistically 
significant (p<0.001) and was maximum in Group II (17.5 mg%) (Gilbenclamide 
and sitagliptin combination) and group V (7.83 mg%) (metformin and sitagliptin 
combination). 
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Figure 10: Line diagram showing HDL cholesterol levels of all 6 groups at 
before and after therapy  
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Table 25: Comparison of serum amylase of the groups before therapy and after 
12 weeks  
 
 
Group 
Treatment 
Duration 
Mean serum amylase 
Std. Deviation 
Mean 
difference 
Group 1 
Baseline 50.93±6.269 
0.200 
12 weeks 50.73±7.153 
Group 2 
Baseline 48.90±8.442 
0.467 
12 weeks 48.43±8.341 
Group 3 
Baseline 37.00±4.371 
0.840 
12 weeks 37.84±4.587 
Group 4 
Baseline 45.63±6.261 
0.632 
12 weeks 45.00±5.970 
Group 5 
Baseline 41.72±6.617 
0.276 
12 weeks 41.45±6.658 
Group 6 
Baseline 58.27±13.663 
0.700 
12 weeks 57.57±13.325 
 
The mean serum amylase levels were unaltered by all the drug combinations and 
the minor changes observed was not statistically significant. 
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DISCUSSION: 
             Diabetes mellitus is a condition in which the body does not produce or 
respond to insulin, a hormone that regulates the level of sugar in the blood. There are 
three types of Diabetes mellitus Type I and Type II diabetes mellitus and gestational 
diabetes mellitus based on the etiology. There are also specific types of diabetes 
mellitus depending on the cause of disease. By 2030, India will be called as capital 
world of diabetes. So far six oral hypoglycaemic agents are available in the market 
due to loss of efficacy and certain limitations, there is necessary for the discovery of 
newer agents. One such agent is DPP-4 inhibitor. It has been found that the incretion 
effect is lost in T2DM and this result in the invention of DPP-4 inhibitors in 
2005.DPP-4 inhibitors acts by inhibiting the DPP-4 enzyme action thereby it increases 
the circulating GLP-1 and GIP levels. GLP-1 acts on the pancreatic Beta cells and 
increases the insulin secretion and GIP acts on the pancreatic alpha cells and reduces 
the glycogen secretion. 
               Sitagliptin, first DPP-4 inhibitor invented in 2006.They have good inhibitory 
effect and well tolerated by elderly people with T2DM.It has not good safety and 
efficacy. It reduces the LDL level and thereby prevents the cardiovascular risk disease 
in elderly people. It has very less hypoglycaemic symptoms and compensates the 
weight gain produced by the other OHA .It reduces FPG, PPG, HBA1C, significantly 
in T2DM patients. Vildagliptin selective potent second DPP-4 inhibitor reduces FPG, 
PPG, HBA1C significantly. There are controversial studies regarding the effect of 
DPP-4 inhibitors on lipid profile. This study is framed to know about the effect of 
these inhibitors on lipid profile.  
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             In this study, mean age of study subjects included was 55 (+ or -) 6 years with 
maximum age group of 60 to 70 years and minimum age group of 30 to 40 years 
respectively. 
The age difference between group IV and group V was found statistically significant 
(P<0.05) compared with other groups. Regarding both male and female were equally 
distributed in all six group. BMI comparison between the certain groups showed 
statistically significant (P<0.05), while group I vs group II and  group IV vs group V 
where satisfactorily significant. In our study there is reduction in FPG at 4
th
,8
th
, 12
th
 
week of therapy in all 6 groups. Group V treated subjects showed significant 
reductions (P<0.001) with mean value of 33.57(+or-)12 at the 4
th
 week and  62(+or-
)19 at the 8
th
 week. Group VI also showed significant reduction in FPG by mean of 
89% with P value (P<0.001). Intergroup comparison of FPG at 4
th
 week showed that 
group II vs group V had significant P value(P <0.01). As a result, Combined therapy 
of metformin and Gliptins  has achieved good glycemic controlled compared to gliptin 
with sulfonylurea group.when we compared group III and group VI treated subjects, it 
was found that metformin c vildagliptin is very effective in controlling FPG when 
compared to sulfonylurea c Vildagliptin with mean difference of 29% and P<0.0001 at 
the group showed statistically significant reduction (P<0001). Vildagliptin add on 
therapy with metformin and sulfonylurea with sitagliptin combination has achieved 
good glycemic control when compared to the controlled group. Add on therapy was 
better than the monotherapy with metformin or sulfonylurea. When we compared 
monotherapy groups, it was found that monotherapy with metformin has given better 
reduction in FPG level than sulfonylurea. 
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                 By comparing the reduction reduction in post prandial glucose levels 
among the groups at the end of 4
th
8th and 12
th
 week, it was found that group V 
subjects showed maximum reduction at 4
th
 week and group VI showed significant 
reduction (P<0.001) with mean of 95% and 132 mg at 8
th
 & 12
th
 week respectively. At 
the end 4th week add on therapy metformin with sitagliptin and sulphonylurea with 
vildagliptin has showed (P<0.001) with mean of 28.73% (group II vs group III) and 
metformin with sitagliptin group II achieved proper glycemic control of post prandial 
glucose than group V with mean of 24.50% and (P<0.009). 8
th
 week results shows that 
group II vs group V, metformin with sitagliptin has achieved good glycemic control 
with mean of 47.86% and (p<0.001). When compared with monotherapy groups 
(group I and group IV), combined therapy are very effective than monotherapy with 
significant (p<0.01) and mean of 49% (group I vs group III).  
                   At the end of 12
th
 week the mean difference in postprandial glucose level 
between the groups were except(group I vs group II, group V vs group VI, group I vs 
group IV). Combined therapy of vildagliptin with sulfonylurea has achieved higher 
glycemic control compared (62 vs 127) to sitagliptin with sulfonylurea. Metformin 
with sitagliptin group has shown higher reduction in PPG level with p<0.01 and mean 
of 60.8% compared with sulfonylurea with sitagliptin groups. Add on therapy has 
showed better reduction in PPG level compared to monotherapy group (group I and 
group V). At the end of 12
th
 week, compared with other groups, group V and VI 
showed significant reduction in HbA1c level with p<0.001. 
               The mean triglyceride level of 133.47(+or_) 12.48 was achieved in all the 
combined group at the end of the 12
th
 week with significant P<0.0001. The Metformin 
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with sitagliptin group has proved significant reduction in triglyceride level compared 
to the other combined groups. Similarly, combined therapy with sitagliptin has 
significantly reduced the LDL-CH level at the end of the 12
th
 week with mean of 
78.23(+ or-) 6.1 with p<0.001.This similar effect was seen in ottavio et al, which 
showed that after 21 weeks with sitagliptin 100 mg has reduced the low density 
lipoprotein levels and there by prevents cardiovascular events, insulin requirements. 
Increase in HDL level was significantly seen in group II therapy (sitagliptin with 
sulfonylurea) and group V at the end of 12
th
 week with P<0.001.The mean total 
cholesterols levels showed that significant reduction is seen in group II(7.7mg %) and 
group VI(5.3mg%) when compared to other groups. 
               At the of 12
th
 week, maximum reduction of tryglyceride is seen in group V 
and group II with mean of 11.3 mgms % and 8.47 mgms%. Similarly maximum 
reduction of low density lipoprotein level is seen in group V and group VI with mean 
of (17.2 mgms%) and (10.63 mgms%) respectively. Among all the groups, the serum 
amylase levels were found un altered throughout the study in all the treated groups. 
              In Braz et al, sitagliptin combined with metformin demonstrated that there is 
significant reduction in FPG by 20.3mg/dl with p<0.05. Similar results was reported 
in this study that metformin and sitagliptin showed significant reduction in FPG,PPG 
after 12 weeks therapy. In a randomized control trial done in 444 patients who were 
treated with combined therapy of sulfonylurea and Sitagliptin over a period of 24 
weeks. Author observed that there is a significant reduction in HbA1c by 0.74%, FPG 
by 20.1mg/dl(p<0.001). In our study the same combined therapy has showed 
significant reduction in FPG,PPG, and HbA1c levels at the end of 12
th
 week 
[52].
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              Bosi et al proved that T2DM patients with inadequate glycemic control when 
treated with (metformin and vildagliptin) combined therapy over a period of 24 
weeks, resulted in significant decrease of FPG,PPG and HbA1c level by 0.7(+or-)% 
and 36(+or-)5 mg/dl respectively. In this study metformin with vildagliptin 
combination therapy has resulted in effective reduction of FPG,PPG and HbA1c levels 
at the end of 12
th
 week 
[53].
 
           In comparative study organized by Ahren and colleagues, T2DM subjects with 
uncontrolled glycemic control following monotherapy with metformin and glimipride 
was treated with vildagliptin 50mg bd over period of 12 weeks. After 12 weeks 
treatment author conducted that vildagliptin combined therapy is very effective 
compared to the monotherapy with glimipride and metformin  
[39].
 
 The present study reported that combined therapy of metformin with 
vildagliptin ,metformin with sitagliptin, sulfonylurea with sitagliptin groups had 
showed an significant reduction in FPG,PPG and HbA1c levels with significant P 
value of P<0.001. As a result, it has been proved that combined therapy is very 
effective when compared to the monotherapy with metformin and sulfonylurea. 
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CONCLUSION: 
           Diabetes mellitus is a major health that accounts for morbidity and mortality. 
There are three categories based on the etiology. Diabetes when not treated properly 
leads to many complication leading to death in severe cases. Many drugs have been 
invented and about six groups are approved and available in the clinical practice. Day 
by day after repeated usage, they lose their property and becomes uneffective with 
adverse effects also. As a result of which newer drugs are invented and the few drugs 
are also under trial for therapy. One among them is Dipeptidyl peptidase -4 inhibitor, 
invented and approved by FDA in 2005 for management of type 2 DM. 
 The incretion defect in type II DM patients was corrupted by DPP-4 inhibitors 
and GLP-1 against drugs. DPP-4 inhibitors act by increasing the incretin hormone 
level by blocking the DPP-4 enzyme action there by increasing the insulin secretion 
by the pancreatic beta cell. There are six DPP-4 inhibitors available in the market. 
Sitagliptin was first DPP-4 inhibitor invented in 2006. They have a new therapeutic 
approach in the therapy of T2DM patients. They are effective both as monotherapy 
and combined therapy with other oral hypoglycemic agents. Sitagliptin significantly 
reduces FPG,PPG, HbA1C levels in type 2 DM patients. They reduce the low density 
liproprotien level their by prevents the risk of cardiovascular events in elderly people. 
It has good safety and efficacy compared to other OHA‟s. It compensates the side 
effects produced  by other OHA‟s such as metformin and sulfonylurea.  It has got less 
hypoglycemic symptom and weight neutralising effect vildagliptin, a second selective 
and potent DPP-4 inhibitor was discovered in February and approved by FDA. Both 
sitagliptin has got good oral bio availability. vildagliptin is well tolerated by elderly 
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people. It is also more effective as monotherapy and combined therapy with other oral 
anti diabetic agents. Vildagliptin significantly reduces the FPG,PPG,HbA1c levels in 
T2DM patients. Patients improve the beta cell function by pharmacodynamic 
remodeling and there by increases the insulin secretion. It has good safety and efficacy 
profile. Many trials proved that vildagliptin 50mg twice daily and sitagliptin 100mg 
once daily is effective and safe for the management of uncontrolled hyperglycemia in 
T2DM patients. The present study showed that sitagliptin and vildagliptin as 
combined therapy with metformin has significantly (p<0.001) reduced FPG, PPG and 
HBA1C in T2DM patients. They also had significant effect on serum lipid profile by 
reducing triglycerides and low density lipoprotein cholesterol after 12 weeks of 
therapy. Combination of metformin with vildagliptin was found to be significantly 
effective in the management of T2DM patients. 
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Limitations of Study: 
 Short duration 
 Minimal Sample size 
 Requires further study to demonstrate the effect of gliptins on 
cardiovascular diseases and their safety and efficacy. 
 
 
 
 
 
 
0 168 200 6.9
4 124 172
8 103 148
12 88 136 6.4
0 174 210 6.9
4 153 172
8 122 151
12 90 138 6.5
0 172 196 7
4 118 170
8 101 149
12 88 134 6.6
0 186 210 7.1
4 128 170
8 112 142
12 94 136 6.8
0 156 170 6.7
4 148 160
8 142 158
12 140 156 6.4
0 170 200 6.9
4 128 176
8 104 142
12 90 136 6.2
0 156 188 6.8
4 129 152
8 116 142
12 78 130 6.1
0 150 180 6.7
4 132 162
8 112 148
12 86 136 6.4
0 174 198 6.9
4 134 171
8 106 150
12 90 134 6.3
0 180 200 6.9
4 156 164
8 121 152
12 90 140 6.2
0 166 188 6.8
11 55 F 156 70
10 56 M 164 94
9 48 M 159 98
8 55 M 161 86
7 61 F 149 74
5 46 M 157 92
4 47 M 154 87
3 54 M 158 75
2 53 M 164 80
1 51 M 161 167
PPBS HBA1C
6 53 F 154 80
GROUP I- SULFONYL UREA(GLIBENCLAMIDE 5mg)
S.NO AGE SEX HEIGHT WEIGHT WEEKS FBS
4 128 154
8 103 141
12 88 130 6.2
0 182 200 6.9
4 140 162
8 121 142
12 90 128 6.5
0 174 190 7
4 128 158
8 100 142
12 86 136 6.8
0 162 180 6.7
4 136 149
8 120 140
12 92 132 6.4
0 148 170 6.6
4 122 146
8 108 132
12 70 129 6.3
0 154 178 6.7
4 122 152
8 106 128
12 82 126 6.2
0 166 183 6.8
4 132 154
8 102 141
12 86 122 6.1
0 146 170 6.7
4 116 152
8 100 136
12 72 130 5.8
0 168 190 6.9
4 132 164
8 109 152
12 78 138 6.1
0 188 220 7.2
4 126 190
8 106 152
12 84 140 6.4
0 180 200 7
4 146 174
8 122 162
12 78 140 6.8
0 166 190 6.9
4 113 171
8 102 154
22 52 F 149 74
21 53 M 159 85
20 57 M 153 89
19 52 F 143 78
18 47 F 145 75
17 58 M 152 108
16 55 M 161 99
15 52 M 153 98
14 62 F 149 69
13 54 F 146 75
12 62 M 159 87
11 55 F 156 70
12 86 136 6.5
0 148 170 6.6
4 119 162
8 98 141
12 72 124 6.4
0 158 176 6.7
4 122 158
8 108 137
12 86 122 6.5
0 154 172 6.8
4 124 154
8 108 138
12 84 128 6.4
0 176 188 6.8
4 132 152
8 102 140
12 86 126 6.4
0 159 174 6.7
4 130 143
8 116 131
12 98 124 6.5
0 144 166 6.7
4 130 150
8 98 132
12 72 130 6.4
0 188 210 7
4 149 196
8 122 189
12 90 200 6.8
0 164 186 6.9
4 151 156
8 114 190
12 80 172 6.6
30 58 M 165 98
29 52 M 156 92
28 48 F 154 84
27 56 M 158 78
26 60 M 161 72
25 55 M 158 98
24 56 M 162 92
23 43 F 151 78
22 52 F 149 74
TC TG LDL HDL
26 0.6 190 138 76 58 45
188 132 74 58 47
24 0.6 186 120 68 56 51
184 119 66 57 48
26 0.8 198 136 78 64 41
194 132 76 67 40
30 0.9 200 140 75 70 52
198 137 73 72 51
21 0.7 170 130 66 62 46
168 127 64 63 44
24 0.3 166 126 76 56 54
161 124 74 57 52
28 0.6 189 140 84 62 61
187 138 83 62 60
21 0.2 159 140 80 72 56
156 137 76 75 54
36 0.8 176 138 66 82 43
175 134 62 84 42
24 0.3 188 148 76 66 47
185 146 74 68 47
26 0.4 186 134 72 54 42
BLOOD UREA SR.CREATININE SERUM AMYLASE
LIPID PROFILE
GROUP I- SULFONYL UREA(GLIBENCLAMIDE 5mg)
184 132 70 56 44
28 0.7 168 130 80 66 64
166 128 78 66 68
21 0.6 194 129 69 62 53
192 126 65 64 59
31 0.7 184 146 74 82 47
183 141 71 86 45
41 0.8 158 128 82 78 52
156 124 81 75 50
24 0.2 176 138 74 52 53
177 136 72 52 50
32 0.6 158 144 82 68 56
156 141 80 69 57
21 0.1 194 126 74 74 42
191 124 72 76 41
24 0.4 172 132 68 66 47
170 131 66 65 49
32 0.8 189 142 72 64 58
186 140 70 61 56
28 0.7 200 120 74 64 47
188 118 72 68 45
24 0.8 174 126 82 58 49
176 129 76 59 50
21 0.7 156 142 68 54 51
159 144 61 56 48
24 0.9 182 134 76 78 54
184 130 70 76 50
28 0.6 166 128 80 72 61
169 126 78 72 65
28 0.7 158 142 80 54 43
154 144 78 56 42
24 0.8 196 124 72 64 47
198 121 71 64 49
27 0.6 178 130 82 56 51
174 128 84 58 56
31 0.6 166 138 70 78 54
161 136 66 79 50
34 0.9 200 134 72 64 61
189 130 70 66 63
0 180 220 6.8
4 162 180
8 146 162
12 94 130 6.2
0 174 200 6.6
4 164 176
8 132 148
12 90 126 6.2
0 170 208 7
4 152 183
8 124 152
12 98 134 6.6
0 180 190 6.8
4 162 168
8 134 150
12 90 136 6.2
0 176 184 6.6
4 156 164
8 124 148
12 100 134 6.1
0 170 180 6.6
4 158 168
8 124 146
12 88 130 6.2
0 162 176 6.8
4 144 156
8 120 142
12 100 132 6.4
0 158 200 6.8
4 132 183
8 120 152
12 102 126 6.1
0 164 184 6.8
4 146 164
8 120 148
12 96 134 6.2
0 180 170 7
4 156 158
8 132 140
12 106 130 6.6
0 170 210 7
4 160 186
8 142 152
12 108 140 6.6
11 54 M 162 108
10 59 M 156 108
9 50 M 162 96
8 64 M 161 89
7 47 F 149 78
6 58 F 146 85
5 58 F 151 68
4 65 F 156 78
3 64 M 164 110
2 61 M 168 96
HBA1C
1 58 F 162 85
GROUP II- SULFONYL UREA+SITAGLIPTIN
S.NO AGE SEX HEIGHT WEIGHT WEEKS FBS PPBS
0 168 190 6.8
4 146 174
8 122 156
12 110 138 6.2
0 180 170 6.8
4 168 156
8 138 140
12 106 130 6.6
0 200 220 6.9
4 180 184
8 148 154
12 110 142 6.5
0 206 210 7.1
4 182 188
8 146 154
12 98 138 6.3
0 170 200 7.1
4 158 182
8 124 162
12 88 136 6.4
0 178 198 6.8
4 158 180
8 130 160
12 110 130 6.4
0 182 184 6.6
4 164 162
8 14 142
12 106 132 6.1
0 176 180 6.6
4 154 168
8 128 146
12 90 130 6.1
0 194 210 7
4 176 180
8 148 158
12 110 142 6.6
0 194 210 7.4
4 172 188
8 140 156
12 110 130 6.7
0 180 186 7
4 162 163
8 136 143
12 100 128 6.2
0 170 182 7.2
4 152 160
8 122 146
12 96 130 6.2
0 200 220 6.9
24 52 M 160 80
23 58 F 163 86
22 53 F 163 84
21 62 M 165 92
20 54 M 154 94
19 46 F 149 78
18 54 M 158 112
17 53 M 155 104
16 62 F 148 89
15 47 F 146 74
14 56 M 158 98
13 55 M 156 96
12 61 F 143 88
4 174 188
8 150 158
12 114 146 6.4
0 168 180 6.8
4 142 160
8 120 152
12 86 132 6.2
0 170 190 6.2
4 156 168
8 120 150
12 90 138 6.3
0 190 210 7
4 168 180
8 140 162
12 110 142 6.6
0 182 200 7
4 162 176
8 134 148
12 100 126 6.2
0 168 180 7.1
4 150 162
8 126 150
12 108 124 6.3
0 200 220 6.9
4 172 180
8 144 158
12 110 130 6.6
30 56 M 146 70
29 53 M 151 92
28 52 F 156 83
27 66 M 160 98
26 45 M 164 87
25 43 F 159 79
24 52 M 160 80
TC TG LDL HDL
40 0.9 182 146 80 52
170 138 72 60
28 0.6 180 146 82 50
172 136 74 58
30 0.9 200 140 82 40
188 136 76 50
36 1 186 138 80 38
180 130 70 52
24 0.9 184 142 78 50
178 136 70 60
28 1 190 146 90 35
182 136 83 65
30 0.9 184 140 88 35
178 134 78 55
30 0.9 190 140 88 40
184 138 76 60
26 1 186 144 90 42
178 136 78 56
24 0.6 180 146 86 42
170 132 74 60
36 0.8 194 148 86 38
182 138 80 55
BLOOD UREA SR.CREATININE
LIPID PROFILE
GROUP II- SULFONYL UREA+SITAGLIPTIN
28 1 186 148 86 30
180 136 76 50
20 0.8 190 138 90 38
184 130 88 58
24 1 180 140 90 50
174 132 80 60
30 0.9 196 140 86 52
188 132 76 60
30 1 180 146 90 34
172 138 80 58
28 1 184 140 90 36
176 130 76 58
26 0.9 190 136 88 50
180 128 80 60
26 0.6 186 140 80 48
182 132 72 64
20 1 194 138 86 40
186 130 72 58
26 0.8 182 150 92 40
176 140 80 60
28 1 180 140 90 40
172 128 80 62
18 1.2 180 136 86 32
170 128 74 58
20 0.9 200 136 80 34
192 130 70 58
24 1 190 130 84 36
182 120 72 60
24 0.9 180 130 86 40
174 122 76 60
20 1 190 130 90 52
183 124 70 68
18 0.6 186 140 80 50
178 130 70 64
30 0.8 184 138 88 40
180 128 68 62
20 0.8 190 140 80 48
180 130 68 68
41
40
52
51
38
38
44
45
46
47
47
46
41
43
39
38
44
44
54
56
52
50
SERUM AMYLASE
47
48
34
30
38
36
45
44
42
44
54
52
58
56
61
60
63
60
58
56
61
60
64
62
48
46
50
53
38
40
47
49
62
64
48
46
51
49
0 123 298 8
4 111 202
8 108 173
12 96 132 6.9
0 140 306 7.4
4 120 237
8 109 169
12 102 128 6
0 136 222 7.6
4 116 108
8 108 143
12 97 109 6.2
0 162 320 7.4
4 139 276
8 118 204
12 102 140 6.4
0 149 272 7.8
4 126 218
8 118 156
12 100 126 6.4
0 184 320 7.2
4 136 240
8 117 187
12 102 138 6.2
0 139 200 7
4 128 163
8 106 129
12 94 107 6.2
0 186 340 7.4
4 136 290
8 120 209
12 108 136 6.1
0 176 273 6.9
4 129 209
8 120 187
12 100 147 6
0 119 170 7.1
4 108 120
8 100 102
12 92 94 6.3
0 146 228 7
4 128 186
8 110 140
12 92 109 6.1
GROUP III- SULFONYL UREA+VILDAGLIPTIN
S.NO AGE SEX HEIGHT WEIGHT WEEKS FBS PPBS HBA1C
1 46 F 160 72
2 50 F 148 56
3 44 M 170 74
4 57 F 156 59
5 60 M 163 54
6 55 M 170 68
7 49 M 163 49
8 53 F 150 64
9 48 M 159 56
10 60 M 164 52
11 59 F 149 68
0 154 242 7.2
4 138 206
8 119 148
12 103 116 6.6
0 160 302 7.5
4 139 273
8 120 218
12 104 110 6.3
0 152 290 6.9
4 136 200
8 108 169
12 93 126 6.2
0 142 209 7.1
4 128 173
8 120 156
12 104 120 6.3
0 146 296 7.2
4 128 222
8 120 128
12 104 120 6
0 140 270 6.9
4 124 236
8 118 175
12 99 129 5.9
0 136 256 6.3
4 128 208
8 119 146
12 107 120 5.5
0 145 290 7.2
4 130 220
8 126 168
12 104 130 6.4
0 160 302 7.9
4 140 256
8 121 184
12 109 140 6.4
0 129 188 7.2
4 108 174
8 100 160
12 94 120 6.3
0 132 200 7
4 118 164
8 112 148
12 103 130 6.2
0 126 176 6.7
4 120 144
8 104 126
12 89 105 5.9
0 149 230 6.6
12 57 F 156 72
13 59 M 179 98
14 49 M 172 86
15 50 M 176 77
16 54 F 152 64
17 49 F 156 51
18 57 M 164 59
19 59 F 173 65
20 43 M 175 85
21 60 F 148 54
22 49 M 168 70
23 54 F 152 63
24 48 F 143 68
4 136 201
8 118 174
12 110 140 6
0 136 260 7.1
4 126 204
8 104 189
12 93 135 6.2
0 140 220 7
4 120 186
8 106 162
12 98 120 6.2
0 140 232 7.2
4 136 170
8 118 120
12 102 106 6.4
0 142 200 7
4 126 156
8 106 130
12 94 110 6.3
0 143 176 7.1
4 129 156
8 109 130
12 98 100 6.3
0 139 179 6.9
4 120 130
8 109 116
12 93 108 6.1
24 48 F 143 68
25 50 F 159 71
26 54 F 138 46
27 56 M 168 75
28 45 M 170 72
29 48 F 163 58
30 60 M 168 82
TC TG LDL HDL
22 0.9 180 109 86 39 32
180 108 77 39 32
28 0.8 172 128 73 45 40
170 128 66 46 38
34 0.9 176 130 59 46 34
174 128 48 46 33
32 1 165 140 86 52 42
162 128 64 53 43
29 0.8 180 130 110 36 38
175 126 98 39 45
28 0.8 192 140 86 45 36
190 136 73 46 38
31 0.9 173 128 59 53 32
172 120 46 55 34
32 0.9 186 129 63 39 41
180 129 55 40 40
34 0.9 176 130 69 42 29
176 130 53 43 30
29 0.8 180 120 58 39 42
180 120 52 43 43
28 0.8 172 123 69 42 40
170 120 60 42 43
GROUP III- SULFONYL UREA+VILDAGLIPTIN
BLOOD UREA SR.CREATININE
LIPID PROFILE
SERUM AMYLASE
32 1 164 131 75 36 36
164 130 65 38 39
29 0.9 180 130 73 41 41
180 128 69 42 44
30 1 190 140 86 39 37
184 136 73 40 34
26 0.9 158 113 63 50 39
158 112 59 50 40
28 0.9 180 126 79 39 32
179 126 64 40 34
32 1 173 148 82 46 38
172 146 73 46 40
32 1.1 154 118 59 52 42
153 118 56 53 44
26 0.8 186 151 88 33 46
179 150 78 39 44
24 0.9 188 150 108 35 38
180 150 90 35 40
26 0.8 180 146 80 51 29
174 144 73 52 30
24 0.9 179 128 76 43 37
168 120 62 43 39
32 1 170 132 86 39 35
170 126 80 43 37
20 0.8 192 129 60 33 37
190 126 51 33 39
31 1.1 178 142 73 50 41
175 140 64 50 43
28 0.8 160 136 84 36 32
160 134 75 36 34
32 0.8 158 130 80 40 38
156 129 71 41 40
26 1 173 138 86 39 29
172 138 75 40 30
30 0.8 180 146 88 36 36
176 145 77 37 35
24 0.9 163 130 69 50 41
162 128 62 52 40
0 124 180 6.9
4 118 160
8 104 148
12 86 126 6
0 130 198 7.1
4 126 172
8 116 156
12 96 134 6.6
0 104 210 7
4 139 172
8 104 139
12 98 160 6.2
0 150 208 6.8
4 126 169
8 108 141
12 92 132 6.4
0 121 184 7.2
4 118 170
8 100 142
12 76 124 6.1
0 139 210 7.1
4 116 196
8 98 154
12 76 138 6.6
0 149 189 6.9
4 128 162
8 94 141
12 78 126 6.5
0 136 229 7.2
4 112 201
8 104 178
12 84 133 6.8
0 154 196 7
4 126 176
8 101 154
12 88 127 6.4
0 162 218 6.8
4 138 194
8 112 156
12 84 136 6.2
0 141 182 7.1
4 108 160
8 99 149
12 79 134 6.2
GROUP IV- METFORMIN
S.NO AGE SEX HEIGHT WEIGHT WEEKS FBS PPBS HBA1C
1 43 M 170 86
2 49 M 173 77
3 54 F 151 50
4 48 M 168 74
5 44 F 156 70
6 49 M 168 69
7 56 F 149 54
8 57 F 152 49
9 60 F 154 72
10 55 F 156 68
11 49 M 175 64
0 126 178 7.3
4 120 159
8 100 128
12 81 109 6.7
0 149 166 6.9
4 112 136
8 104 120
12 86 116 6
0 134 186 7.2
4 112 139
8 100 128
12 78 124 6.8
0 192 220 7.3
4 128 170
8 108 152
12 94 138 6.6
0 168 220 7.4
4 132 184
8 109 146
12 96 132 7
0 154 191 6.8
4 126 152
8 112 139
12 81 123 6.2
0 164 196 6.9
4 109 150
8 98 138
12 92 118 6.4
0 110 162 6.6
4 98 136
8 94 112
12 75 109 6.1
0 138 186 6.9
4 101 160
8 90 142
12 79 137 6.2
0 164 220 7.5
4 129 169
8 99 142
12 84 131 7
0 134 166 7.1
4 112 128
8 94 114
12 72 109 6.9
0 168 242 7.8
4 114 194
8 102 138
12 87 128 6.7
0 144 261 7
12 57 M 170 76
13 53 F 163 70
14 47 F 148 58
15 48 M 159 84
16 56 F 163 73
17 47 F 159 64
18 60 M 175 80
19 53 F 136 70
20 58 M 167 76
21 62 M 176 88
22 61 M 179 75
23 52 F 158 75
24 51 F 168 84
4 108 171
8 86 152
12 76 134 5.9
0 168 229 7.3
4 120 164
8 109 132
12 82 114 6.1
0 174 218 7.1
4 129 172
8 102 146
12 82 136 6.8
0 167 194 6.9
4 148 143
8 112 138
12 91 128 6.1
0 150 195 6.8
4 124 156
8 101 140
12 75 131 6.2
0 128 188 6.7
4 102 152
8 96 141
12 72 124 6.1
0 161 226 7.2
4 126 182
8 100 143
12 87 134 6.6
24 51 F 168 84
25 64 M 170 54
26 42 M 159 56
27 51 M 168 72
28 61 F 148 68
29 52 M 173 89
30 52 F 149 63
TC TG LDL HDL
24 0.6 176 134 86 43 41
170 130 82 43 41
26 0.2 152 124 81 52 45
150 123 80 54 45
32 0.8 164 132 76 47 39
161 130 74 47 38
21 0.9 175 137 82 54 48
172 135 80 55 47
18 0.7 168 141 79 49 52
165 140 77 49 51
24 0.4 178 132 75 42 41
175 130 71 42 39
28 0.8 162 128 80 49 38
160 126 79 49 36
34 0.9 158 121 74 47 54
157 120 72 48 52
40 0.9 173 134 84 46 44
170 133 83 47 44
22 0.6 178 126 88 42 53
176 125 87 43 50
28 0.2 172 136 78 45 41
172 135 77 46 40
GROUP IV- METFORMIN
BLOOD UREA SR.CREATININE
LIPID PROFILE
SERUM AMYLASE
18 0.1 161 124 82 52 38
160 122 80 53 38
24 0.6 159 132 76 58 45
157 130 75 58 44
30 0.4 164 138 79 49 47
162 135 77 49 44
32 0.2 179 131 80 45 51
177 130 79 46 50
28 0.6 182 136 78 42 48
180 134 77 40 47
32 0.8 178 128 84 44 51
176 125 81 45 49
21 0.2 174 136 82 41 38
172 134 80 42 38
18 0.4 156 124 72 48 58
154 122 70 49 57
22 0.6 174 138 78 44 46
172 135 76 45 44
24 0.2 174 129 78 49 44
172 127 75 49 42
21 0.4 166 134 76 51 37
164 132 74 52 37
18 0.8 182 139 68 52 41
180 135 66 52 41
26 0.7 173 128 77 46 34
172 126 76 46 33
32 0.9 162 134 84 52 51
160 132 81 53 50
28 7.1 176 132 76 48 42
174 130 74 49 40
30 0.8 182 138 84 46 54
180 135 82 47 53
22 0.2 178 128 76 41 48
176 126 75 43 46
18 0.4 186 134 87 54 56
184 132 85 55 54
24 0.6 184 126 82 43 44
182 124 80 44 44
0 170 260 7.6
4 148 211
8 112 167
12 105 129 6.4
0 196 222 7.2
4 162 171
8 108 132
12 80 110 6.4
0 164 276 7.3
4 116 218
8 94 156
12 72 137 6.1
0 141 219 7.9
4 109 182
8 92 134
12 78 117 6.6
0 189 288 8
4 148 211
8 104 156
12 87 131 5.9
0 158 291 7.4
4 103 214
8 86 162
12 72 136 6.2
0 179 263 7.1
4 124 208
8 86 156
12 94 142 5.6
0 131 241 7.5
4 98 198
8 82 145
12 74 129 6.8
0 126 246 7.8
4 107 204
8 82 173
12 77 134 6
0 146 227 7
4 106 198
8 84 152
12 66 124 5.3
0 147 267 77
4 123 194
8 108 142
12 74 129 6.1
GROUP V- METFORMIN + SITAGLIPTIN
S.NO AGE SEX HEIGHT WEIGHT WEEKS FBS PPBS HBA1C
1 58 F 152 54
2 62 M 164 68
3 50 F 150 58
4 65 M 168 70
5 68 M 162 76
6 56 F 154 60
7 58 F 152 58
8 66 M 162 74
9 62 M 170 72
10 48 F 164 64
11 68 M 168 74
0 162 253 7.4
4 134 214
8 106 142
12 87 116 6.6
0 159 182 7.9
4 123 168
8 97 136
12 74 116 5.8
0 212 314 8.2
4 163 235
8 127 181
12 104 147 6.4
0 186 228 7.9
4 147 184
8 110 158
12 88 127 5.5
0 162 234 7.3
4 126 196
8 104 154
12 81 136 5.8
0 138 187 7.6
4 112 152
8 94 138
12 71 114 6.1
0 164 228 7.8
4 138 186
8 107 158
12 74 114 6.4
0 158 284 8
4 126 246
8 101 178
12 83 127 6.3
0 176 218 7.3
4 142 192
8 108 164
12 71 124 5.8
0 174 236 7.4
4 121 197
8 96 152
12 67 123 6
0 186 227 7.9
4 145 184
8 116 158
12 78 134 6.4
0 154 242 7.3
4 126 216
8 102 164
12 78 126 5.8
0 147 279 8.1
12 54 F 152 54
13 60 M 164 68
14 63 M 162 76
15 52 F 156 58
16 54 F 156 60
17 48 F 158 58
18 60 M 168 72
19 66 M 164 76
20 58 M 172 70
21 64 M 170 68
22 66 M 166 72
23 52 F 156 52
24 65 M 164 78
4 122 225
8 94 158
12 72 118 6.6
0 136 284 7.8
4 119 216
8 99 171
12 74 136 5.8
0 182 229 7.5
4 158 192
8 124 167
12 78 136 6.1
0 167 246 7.1
4 142 208
8 116 164
12 64 128 5.8
0 146 265 7.8
4 124 237
8 104 173
12 82 121 6.2
0 124 276 8.1
4 116 241
8 99 182
12 78 137 6.3
0 236 282 8.3
4 181 184
8 114 158
12 86 106 6.1
24 65 M 164 78
25 58 F 152 52
26 60 M 168 74
27 58 F 154 54
28 50 F 156 58
29 65 M 170 76
30 62 M 168 72
TC TG LDL HDL
22 0.7 179 161 96 62 41
188 132 74 58 47
18 0.5 142 146 110 45 36
148 138 82 52 36
16 0.4 174 181 118 42 44
182 149 86 54 43
26 0.8 168 144 98 78 47
161 138 76 71 47
19 0.3 172 136 85 67 51
174 128 71 69 50
21 191 143 110 58 47
182 138 91 69 46
30 1 164 162 118 57 32
162 156 84 59 32
17 0.5 186 147 92 61 36
188 138 81 64 36
19 0.4 156 154 112 57 48
159 138 91 62 47
24 0.6 184 162 96 58 42
186 148 81 61 42
26 0.9 178 148 98 58 32
174 136 81 61 30
GROUP V- METFORMIN + SITAGLIPTIN
BLOOD UREA SR.CREATININE
LIPID PROFILE
SERUM AMYLASE
27 0.7 186 141 88 59 44
182 124 74 64 44
16 0.3 168 138 91 54 35
162 123 78 58 34
19 0.8 186 156 118 54 42
178 141 86 65 42
23 0.5 192 136 92 59 37
184 128 84 68 36
19 0.2 188 136 98 58 41
184 134 82 65 40
29 0.7 193 144 88 54 34
186 136 72 68 34
14 1 182 148 88 42 33
178 132 72 55 33
32 0.3 176 146 96 57 46
172 138 82 62 45
23 0.5 168 148 86 51 42
161 132 71 68 42
14 0.4 186 142 88 57 45
188 138 71 62 44
22 0.8 198 139 92 43 47
182 132 74 61 46
26 0.2 184 141 92 51 42
182 136 78 64 42
30 0.9 178 146 87 45 38
172 131 64 68 38
18 0.5 169 148 92 56 36
162 134 78 67 35
22 0.2 188 156 110 55 38
176 148 84 62 38
33 0.8 196 141 96 44 42
182 138 81 58 41
21 0.6 196 136 92 56 47
188 132 78 67 47
18 2.1 176 147 92 58 51
168 136 86 66 51
11 6.4 194 138 98 54 61
182 132 76 69 60
TC TG LDL HDL
0 126 243 7.2 24 0.7 176 133 68 41 46
4 118 214
8 92 148
12 74 108 5.8 174 126 61 42 45
0 194 268 7.2 28 0.9 186 144 83 34 52
4 163 243
8 118 189
12 82 114 6.4 181 133 74 37 52
0 131 29 7.8 32 0.6 180 139 84 48 64
4 116 265
8 87 178
12 74 136 6.1 176 126 70 49 63
0 123 246 6.9 21 0.4 183 141 69 48 43
4 110 204
8 91 168
12 71 122 5.5 180 133 65 48 40
0 232 296 7.8 26 0.1 194 152 79 38 78
4 184 211
8 126 158
12 85 138 6.4 190 146 70 40 74
0 149 237 7.6 34 0.3 160 146 51 52 62
4 116 182
8 82 148
12 68 126 6.5 158 124 57 52 60
0 182 251 7.3 26 0.9 170 142 64 40 55
4 128 196
8 94 143
12 84 116 5.8 164 129 56 41 51
0 164 249 7.4 24 0.5 173 144 65 39 42
4 118 170
8 86 142
12 71 134 6.2 165 136 57 42 43
0 197 283 7.8 32 0.8 204 187 98 35 38
4 124 206
8 92 173
12 85 137 6.1 196 174 79 40 39
9 68 M 166 94
8 54 M 158 114
7 58 M 156 99
6 61 F 145 84
5 63 M 164 87
4 65 F 146 74
3 58 F 156 82
2 60 M 151 110
HBA1C SR.CREATININE
LIPID PROFILE SERUM 
AMYLASE
1 55 M 160 98
GROUP VI- METFORMIN+VILDAGLIPTIN
S.NO AGE SEX HEIGHT WEIGHT WEEKS FBS PPBS BLOOD UREA
0 146 231 7 23 0.4 168 138 64 42 47
4 128 185
8 93 149
12 68 128 5.4 164 126 55 45 43
0 173 293 7.6 28 0.4 180 109 86 39 58
4 134 226
8 106 168
12 78 127 6.2 180 108 77 40 55
0 164 236 7.4 26 0.9 183 112 84 42 72
4 138 184
8 106 149
12 81 112 6.1 174 110 76 42 70
0 156 294 6.8 34 1 185 140 86 53 61
4 133 204
8 106 173
12 74 137 6 180 129 69 53 58
0 141 276 7.1 18 0.1 168 138 75 36 83
4 136 203
8 109 164
12 93 128 5.4 164 131 64 38 81
0 158 238 7.3 16 0.4 192 144 85 39 74
4 133 194
8 114 146
12 76 106 6.1 181 136 70 41 73
0 148 256 7.4 34 0.6 172 136 86 36 43
4 128 202
8 99 164
12 62 128 6 170 133 76 37 41
0 186 293 8 26 0.4 184 146 88 39 56
4 150 220
8 122 169
12 94 128 6.2 181 140 74 42 54
0 162 310 8 14 0.2 198 154 86 39 68
4 136 256
8 113 174
12 101 139 6.9 192 139 69 40 65
18 56 F 149 73
17 63 M 158 98
16 57 M 163 118
15 67 M 167 114
14 58 F 156 78
13 60 F 148 86
12 54 M 162 96
11 62 M 154 89
10 58 F 148 76
0 154 261 7.5 16 0.6 172 148 84 43 77
4 138 216
8 102 159
12 82 117 6.1 169 136 71 45 75
0 167 245 7.4 26 0.2 179 128 76 43 49
4 141 198
8 120 136
12 97 109 6.2 168 120 63 47 47
0 141 242 7.2 34 0.9 179 133 76 45 58
4 124 204
8 103 169
12 81 126 6 171 126 64 47 56
0 167 274 7.4 13 0.6 183 149 60 38 61
4 143 241
8 114 187
12 74 128 5.6 179 126 50 39 62
0 188 296 8 18 0.3 187 151 88 33 47
4 164 248
8 123 163
12 89 122 6.6 178 146 73 39 49
0 194 313 8.1 22 0.1 186 150 108 35 74
4 153 241
8 116 172
12 84 138 6.4 182 150 90 39 73
0 188 275 7.8 28 0.8 174 138 59 53 88
4 166 249
8 128 174
12 74 124 6.3 170 134 47 53 86
0 184 248 7.4 14 0.6 176 138 70 40 52
4 158 216
8 123 164
12 79 122 6.3 173 129 65 43 51
26 60 M 166 87
25 45 M 162 103
24 38 M 166 98
23 48 F 147 83
22 44 M 158 94
21 63 M 154 107
20 58 F 165 83
19 64 M 152 96
0 193 269 7.6 19 0.2 179 146 80 38 47
4 148 218
8 109 174
12 78 131 5.4 176 148 70 40 46
0 183 293 7.9 28 0.8 183 148 83 46 54
4 151 215
8 109 172
12 74 136 6.4 176 141 74 46 55
0 174 272 7.1 34 0.6 187 149 85 45 62
4 146 208
8 118 164
12 73 134 5.7 176 142 73 47 61
0 194 246 7.6 20 0.2 168 132 71 39 37
4 163 204
8 108 159
12 78 124 6.3 162 127 63 42 35
30 59 M 164 96
29 56 M 156 118
28 49 F 159 78
27 41 F 149 86
CASE SHEET 
Registration no:        Date:  
 
Name:      Age:    Sex: 
 
Address: 
 
Occupation:     Marital Status:   Weight (Kg):    
   
 
Height (Cm):        BMI:       
 
Chief Complaints: 
 
 
H/o Present illness: 
 
 
Past History: 
 
 
Personal History: 
 
 
Family History: 
 
 
Obstetric History: 
 
 
 
Treatment History: 
 
 
General Examination: 
 
BP: 
PR: 
Temp: 
RR: 
Systemic examination:  
 
 
Investigation: 
  Plasma glycosylated haemoglobin (HbA1C) 
  Fasting blood sugar 
  Postprandial blood sugar 
  Lipid profile- Total cholesterol, Triglycerides, High density Lipoprotein, Low density Lipoprotein 
  Urea 
  Serum Creatinine  
  Serum Amylase 
 
Treatment:  
 
 
  Signature of the Investigator 
CONSENT FORM 
(To be obtained from subject) 
Introduction: 
             You are requested to participate in a study conducted in department of 
Pharmacology, Chennai Medical College Hospital & Research Centre, Irungalur, 
Tiruchirapalli, Tamil Nadu entitled. 
“The comparative study of effect of sitagliptin and vildagliptin on glycaemic control 
And serum lipid level in type II diabetic mellitus patients in a rural tertiary care 
hospital” 
 Your participation in this study is Voluntary. You at liberty to participate/ 
withdraw from the study. Please read this consent form carefully and ask the Consultant, 
any questions you may have about the study before signing. 
Explanation of Procedure: 
 If you agree to participate in this study, we will ask some question to you and 
collect relevant information/ Blood sample. You may be examined by the investigator, 
data from the study will be used for research purposes only. The results of the study will 
not to be given to you directly. There will be no cost to you participating in this study. 
Potential benefits: 
 Your participation will help us to know the risk factor of this problem and results 
of this study will be beneficial for future generations. 
Assurance of Confidentiality: 
 The information concerning your participation in the study will be kept 
confidential to the full extent permitted by law and used only for scientific purposes. No 
one except members of the research team will have access the results. Your name will not 
be disclosed in any report or released in any way. 
Patient Consent: 
 I have read the explanation about this study and have been given an opportunity to 
discuss it and to ask questions. I have not received any money for participating in this 
study. 
 
 
Signature of Subject   Signature of Witness    Date 
 
 
     Signature of Researcher 
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